[Congressional Record Volume 164, Number 103 (Wednesday, June 20, 2018)]
[House]
[Pages H5304-H5325]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]




   COORDINATED RESPONSE THROUGH INTERAGENCY STRATEGY AND INFORMATION 
                              SHARING ACT

  Mr. MITCHELL. Mr. Speaker, I move to suspend the rules and pass the 
bill (H.R. 5925) to codify provisions relating to the Office of 
National Drug Control, and for other purposes, as amended.
  The Clerk read the title of the bill.
  The text of the bill is as follows:

                               H.R. 5925

       Be it enacted by the Senate and House of Representatives of 
     the United States of America in Congress assembled,

     SECTION 1. SHORT TITLE.

       This Act may be cited as the ``Coordinated Response through 
     Interagency Strategy and Information Sharing Act'' or the 
     ``CRISIS Act''.

     SEC. 2. OFFICE OF NATIONAL DRUG CONTROL.

       (a) Redesignation.--The Office of National Drug Control 
     Policy shall be known as the ``Office of National Drug 
     Control''.
       (b) References.--Any reference in any other Federal law, 
     Executive order, rule, regulation, or delegation of 
     authority, or any document of or relating to the Office of 
     National Drug Control Policy is deemed to refer to the Office 
     of National Drug Control.
       (c) Codification.--Subtitle I of title 31, United States 
     Code, is amended by adding at the end the following new 
     chapter:

             ``CHAPTER 10--OFFICE OF NATIONAL DRUG CONTROL

                         ``subchapter i--office

``1001. Definitions.
``1002. Office of National Drug Control.
``1003. Administration of the Office.
``1004. National drug control program budget.
``1005. National drug control strategy.
``1006. Development of an annual national drug control assessment.
``1007. Monitoring and evaluation of national drug control program.
``1008. Coordination and oversight of the national drug control 
              program.

[[Page H5305]]

``1009. Emerging threats task force, plan, campaign.
``1010. National and international coordination.
``1011. Interdiction.
``1012. Treatment coordinator.
``1013. Critical information coordination.
``1014. Authorization of appropriations.

         ``subchapter ii--drug-free communities support program

``1021. Establishment of drug-free communities support program.
``1022. Program authorization.
``1023. Information collection and dissemination with respect to grant 
              recipients.
``1024. Technical assistance and training.
``1025. Supplemental grants for coalition mentoring activities.
``1026. Authorization for National Community Antidrug Coalition 
              Institute.
``1027. Definitions.
``1028. Drug-free communities reauthorization.

                         ``SUBCHAPTER I--OFFICE

     ``Sec. 1001. Definitions

       ``In this chapter:
       ``(1) Agency.--The term `agency' has the meaning given the 
     term `executive agency' in section 102.
       ``(2) Appropriate congressional committees.--
       ``(A) In general.--The term `appropriate congressional 
     committees' means--
       ``(i) the Committee on the Judiciary, the Committee on 
     Appropriations, the Committee on Health, Education, Labor, 
     and Pensions, and the Caucus on International Narcotics 
     Control of the Senate; and
       ``(ii) the Committee on Oversight and Government Reform, 
     the Committee on the Judiciary, the Committee on Energy and 
     Commerce, and the Committee on Appropriations of the House of 
     Representatives.
       ``(B) Submission to congress.--Any submission to Congress 
     shall mean submission to the appropriate congressional 
     committees.
       ``(3) Demand reduction.--The term `demand reduction' means 
     any activity conducted by a National Drug Control Program 
     Agency, other than an enforcement activity, that is intended 
     to reduce or prevent the use of drugs or support or provide 
     treatment and recovery efforts, including--
       ``(A) education about the dangers of illicit drug use;
       ``(B) services, programs, or strategies to prevent 
     substance use disorder, including evidence-based education 
     campaigns, community-based prevention programs, collection 
     and disposal of unused prescription drugs, and services to 
     at-risk populations to prevent or delay initial use of an 
     illicit drug;
       ``(C) substance use disorder treatment;
       ``(D) illicit drug use research;
       ``(E) drug-free workplace programs;
       ``(F) drug testing, including the testing of employees;
       ``(G) interventions for illicit drug use and dependence;
       ``(H) expanding availability of access to health care 
     services for the treatment of substance use disorders;
       ``(I) international drug control coordination and 
     cooperation with respect to activities described in this 
     paragraph;
       ``(J) pre- and post-arrest criminal justice interventions 
     such as diversion programs, drug courts, and the provision of 
     evidence-based treatment to individuals with substance use 
     disorders who are arrested or under some form of criminal 
     justice supervision, including medication assisted treatment;
       ``(K) other coordinated and joint initiatives among 
     Federal, State, local, and Tribal agencies to promote 
     comprehensive drug control strategies designed to reduce the 
     demand for, and the availability of, illegal drugs;
       ``(L) international illicit drug use education, prevention, 
     treatment, recovery, research, rehabilitation activities, and 
     interventions for illicit drug use and dependence; and
       ``(M) research related to any of the activities described 
     in this paragraph.
       ``(4) Director.--The term `Director' means the Director of 
     the Office of National Drug Control.
       ``(5) Drug.--The term `drug' has the meaning given the term 
     `controlled substance' in section 102(6) of the Controlled 
     Substances Act (21 U.S.C. 802(6)).
       ``(6) Drug control.--The term `drug control' means any 
     activity conducted by a National Drug Control Program Agency 
     involving supply reduction or demand reduction.
       ``(7) Emerging drug threat.--The term `emerging drug 
     threat' means the occurrence of a new and growing trend in 
     the use of an illicit drug or class of drugs, including rapid 
     expansion in the supply of or demand for such drug.
       ``(8) Illicit drug use; illicit drugs; illegal drugs.--The 
     terms `illicit drug use', `illicit drugs', and `illegal 
     drugs' include the illegal or illicit use of prescription 
     drugs.
       ``(9) Law enforcement.--The term `law enforcement' or `drug 
     law enforcement' means all efforts by a Federal, State, 
     local, or Tribal government agency to enforce the drug laws 
     of the United States or any State, including investigation, 
     arrest, prosecution, and incarceration or other punishments 
     or penalties.
       ``(10) National drug control program.--The term `National 
     Drug Control Program' means programs, policies, and 
     activities undertaken by National Drug Control Program 
     Agencies pursuant to the responsibilities of such agencies 
     under the National Drug Control Strategy, including any 
     activities involving supply reduction, demand reduction, or 
     State, local, and Tribal affairs.
       ``(11) National drug control program agency.--The term 
     `National Drug Control Program Agency' means any agency (or 
     bureau, office, independent agency, board, division, 
     commission, subdivision, unit, or other component thereof) 
     that is responsible for implementing any aspect of the 
     National Drug Control Strategy, including any agency that 
     receives Federal funds to implement any aspect of the 
     National Drug Control Strategy, but does not include any 
     agency that receives funds for drug control activity solely 
     under the National Intelligence Program or the Military 
     Intelligence Program.
       ``(12) National drug control strategy; strategy.--The term 
     `National Drug Control Strategy' or `Strategy' means the 
     strategy developed and submitted to Congress under section 
     1005.
       ``(13) Nonprofit organization.--The term `nonprofit 
     organization' means an organization that is described in 
     section 501(c)(3) of the Internal Revenue Code of 1986 and 
     exempt from tax under section 501(a) of such Code.
       ``(14) Office.--The term `Office' means the Office of 
     National Drug Control.
       ``(15) State, local, and tribal affairs.--The term `State, 
     local, and Tribal affairs' means domestic activities 
     conducted by a National Drug Control Program Agency that are 
     intended to reduce the availability and use of illegal drugs, 
     including--
       ``(A) coordination and enhancement of Federal, State, 
     local, and Tribal law enforcement drug control efforts;
       ``(B) coordination and enhancement of efforts among 
     National Drug Control Program Agencies and State, local, and 
     Tribal demand reduction and supply reduction agencies;
       ``(C) coordination and enhancement of Federal, State, 
     local, and Tribal law enforcement initiatives to gather, 
     analyze, and disseminate information and law enforcement 
     intelligence relating to drug control among domestic law 
     enforcement agencies; and
       ``(D) other coordinated and joint initiatives among 
     Federal, State, local, and Tribal agencies to promote 
     comprehensive drug control strategies designed to reduce the 
     demand for, and the availability of, illegal drugs.
       ``(16) Substance use disorder treatment.--The term 
     `substance use disorder treatment' means an evidence-based, 
     professionally directed, deliberate, and planned regimen 
     including evaluation, observation, medical monitoring, and 
     rehabilitative services and interventions such as 
     pharmacotherapy, behavioral therapy, and individual and group 
     counseling, on an inpatient or outpatient basis, to help 
     patients with substance use disorder reach recovery.
       ``(17) Supply reduction.--The term `supply reduction' means 
     any activity or program conducted by a National Drug Control 
     Program Agency that is intended to reduce the availability or 
     use of illegal drugs in the United States or abroad, 
     including--
       ``(A) law enforcement outside the United States;
       ``(B) domestic law enforcement;
       ``(C) source country programs, including economic 
     development programs primarily intended to reduce the 
     production or trafficking of illicit drugs;
       ``(D) activities to control international trafficking in, 
     and availability of, illegal drugs, including--
       ``(i) accurate assessment and monitoring of international 
     drug production and interdiction programs and policies; and
       ``(ii) coordination and promotion of compliance with 
     international treaties relating to the production, 
     transportation, or interdiction of illegal drugs;
       ``(E) activities to conduct and promote international law 
     enforcement programs and policies to reduce the supply of 
     drugs;
       ``(F) activities to facilitate and enhance the sharing of 
     domestic and foreign intelligence information among National 
     Drug Control Program Agencies, relating to the production and 
     trafficking of drugs in the United States and in foreign 
     countries;
       ``(G) activities to prevent the diversion of drugs for 
     their illicit use; and
       ``(H) research related to any of the activities described 
     in this paragraph.

     ``Sec. 1002. Office of National Drug Control

       ``(a) Establishment of Office.--There is established in the 
     Executive Office of the President an Office of National Drug 
     Control, which shall--
       ``(1) lead the national drug control effort, including 
     coordinating with Nation Drug Control Program Agencies;
       ``(2) coordinate and oversee the implementation of the 
     national drug control policy, including the National Drug 
     Control Strategy;
       ``(3) assess and certify the adequacy of National Drug 
     Control Programs and the budget for those programs;
       ``(4) monitor and evaluate the effectiveness of national 
     drug control policy efforts, including the National Drug 
     Control Program Agencies' programs, by developing and 
     applying specific goals and performance measurements and 
     tracking program-level spending;
       ``(5) identify and respond to emerging drug threats related 
     to illicit drug use;

[[Page H5306]]

       ``(6) administer and evaluate grant programs in furtherance 
     of the National Drug Control Strategy; and
       ``(7) facilitate broad-scale information sharing and data 
     standardization among Federal, State, and local entities to 
     support the national drug control efforts.
       ``(b) Director of National Drug Control and Deputy 
     Director.--
       ``(1) Director.--
       ``(A) In general.--There shall be at the head of the Office 
     a Director who shall hold the same rank and status as the 
     head of an executive department listed in section 101 of 
     title 5.
       ``(B) Appointment.--The Director shall be appointed by the 
     President, by and with the advice and consent of the Senate, 
     and shall serve at the pleasure of the President.
       ``(2) Deputy director.--
       ``(A) In general.--There shall be a Deputy Director who 
     shall report directly to the Director, be appointed by the 
     President, and serve at the pleasure of the President.
       ``(B) Responsibilities.--The Deputy Director shall--
       ``(i) carry out the responsibilities delegated by the 
     Director; and
       ``(ii) be responsible for effectively coordinating with the 
     each Coordinator established under this chapter.
       ``(c) Responsibilities.--
       ``(1) Policies, goals, objectives, and priorities.--The 
     Director shall assist the President in directing national 
     drug control efforts, including establishing policies, goals, 
     objectives, and priorities for the National Drug Control 
     Program that are based on evidence-based research.
       ``(2) Consultation.--To formulate the National Drug Control 
     policies, goals, objectives, and priorities, the Director--
       ``(A) shall consult with--
       ``(i) State and local governments;
       ``(ii) National Drug Control Program Agencies;
       ``(iii) each committee, working group, council, or other 
     entity established under this chapter, as appropriate;
       ``(iv) the public;
       ``(v) appropriate congressional committees; and
       ``(vi) any other person in the discretion of the Director; 
     and
       ``(B) may--
       ``(i) establish advisory councils;
       ``(ii) acquire data from agencies; and
       ``(iii) request data from any other entity.

     ``Sec. 1003. Administration of the Office

       ``(a) Employment.--
       ``(1) Authority of the director.--The Director may select, 
     appoint, employ, and fix compensation of such officers and 
     employees of the Office as may be necessary to carry out the 
     functions of the Office under this chapter.
       ``(2) Prohibitions.--
       ``(A) Generally.--No person shall serve as Director or 
     Deputy Director while serving in any other position in the 
     Federal Government.
       ``(B) Prohibition on political campaigning.--Any officer or 
     employee of the Office who is appointed to that position by 
     the President, by and with the advice and consent of the 
     Senate, may not participate in Federal election campaign 
     activities, except that such officer or employee is not 
     prohibited by this subparagraph from making contributions to 
     individual candidates.
       ``(b) Prohibition on the Use of Funds for Political 
     Campaigns or Ballot Initiatives.--No funds authorized under 
     this chapter may be obligated for the purpose of influencing 
     any Federal, State, or local election or ballot initiative.
       ``(c) Personnel Detailed to Office.--
       ``(1) Evaluations.--Notwithstanding any provision of 
     chapter 43 of title 5, the Director shall perform the 
     evaluation of the performance of any employee detailed to the 
     Office for purposes of the applicable performance appraisal 
     system established under such chapter for any rating period, 
     or part thereof, that such employee is detailed to the 
     Office.
       ``(2) Compensation.--
       ``(A) Bonus payments.--Subject to the availability of 
     appropriations, the Director may provide periodic bonus 
     payments to any employee detailed to the Office.
       ``(B) Restrictions.--An amount paid under this paragraph to 
     an employee for any period--
       ``(i) shall not be greater than 20 percent of the basic pay 
     paid or payable to such employee for such period; and
       ``(ii) shall be in addition to the basic pay of such 
     employee.
       ``(C) Aggregate amount.--The aggregate amount paid during 
     any fiscal year to an employee detailed to the Office as 
     basic pay, awards, bonuses, and other compensation shall not 
     exceed the annual rate payable at the end of such fiscal year 
     for positions at level III of the Executive Schedule.
       ``(d) Congressional Access to Information.--The location of 
     the Office in the Executive Office of the President shall not 
     be construed as affecting access by Congress, or any 
     committee of the House of Representatives or the Senate, to 
     any--
       ``(1) information, document, or study in the possession of, 
     or conducted by or at the direction of the Director; or
       ``(2) personnel of the Office.
       ``(e) Other Authorities of the Director.--In carrying out 
     this chapter, the Director may--
       ``(1) use for administrative purposes, on a reimbursable 
     basis, the available services, equipment, personnel, and 
     facilities of Federal, State, and local agencies;
       ``(2) procure the services of experts and consultants in 
     accordance with section 3109 of title 5 relating to 
     appointments in the Federal Service, at rates of compensation 
     for individuals not to exceed the daily equivalent of the 
     rate of pay payable under level IV of the Executive Schedule 
     under section 5311 of such title; and
       ``(3) use the mails in the same manner as any other agency.
       ``(f) General Services Administration.--The Administrator 
     of General Services shall provide to the Director, on a 
     reimbursable basis, such administrative support services as 
     the Director may request.

     ``Sec. 1004. National drug control program budget

       ``(a) Budget Recommendations.--Not later than July 1 of 
     each year, the Director shall provide to the head of each 
     National Drug Control Program Agency budget recommendations, 
     including requests for specific initiatives that are 
     consistent with the priorities of the President under the 
     National Drug Control Strategy, which shall--
       ``(1) apply to the budget for the next fiscal year 
     scheduled for formulation under chapter 11, and each of the 4 
     subsequent fiscal years; and
       ``(2) address funding priorities developed in the National 
     Drug Control Strategy.
       ``(b) Responsibilities of National Drug Control Program 
     Agencies.--
       ``(1) In general.--For each fiscal year, the head of each 
     National Drug Control Program Agency shall transmit to the 
     Director a copy of the proposed drug control budget request 
     of such agency at the same time as that budget request is 
     submitted to their superiors (and before submission to the 
     Office of Management and Budget) in the preparation of the 
     budget of the President submitted to Congress under section 
     1105(a).
       ``(2) Submission of drug control budget requests.--The head 
     of each National Drug Control Program Agency shall ensure 
     timely development and submission to the Director of each 
     proposed drug control budget request transmitted pursuant to 
     this subsection, in such format as may be designated by the 
     Director with the concurrence of the Director of the Office 
     of Management and Budget.
       ``(3) Content of drug control budget requests.--A drug 
     control budget request submitted by the head of a National 
     Drug Control Program Agency under this subsection shall 
     include all requests for funds for any drug control activity 
     undertaken by such agency, including demand reduction, supply 
     reduction, and State, local, and Tribal affairs, including 
     any drug law enforcement activities. If an activity has both 
     drug control and nondrug control purposes or applications, 
     such agency shall estimate by a documented calculation the 
     total funds requested for that activity that would be used 
     for drug control, and shall set forth in its request the 
     basis and method for making the estimate.
       ``(c) Review and Certification of Budget Requests and 
     Budget Submissions of National Drug Control Program 
     Agencies.--
       ``(1) In general.--The Director shall review each drug 
     control budget request submitted to the Director under 
     subsection (b).
       ``(2) Review of budget requests.--
       ``(A) Inadequate requests.--If the Director concludes that 
     a budget request submitted under subsection (b) is 
     inadequate, in whole or in part, to implement the objectives 
     of the National Drug Control Strategy with respect to the 
     agency or program at issue for the year for which the request 
     is submitted, the Director shall submit to the head of the 
     applicable National Drug Control Program Agency a written 
     description identifying the funding levels and specific 
     initiatives that would, in the determination of the Director, 
     make the request adequate to implement those objectives.
       ``(B) Adequate requests.--If the Director concludes that a 
     budget request submitted under subsection (b) is adequate to 
     implement the objectives of the National Drug Control 
     Strategy with respect to the agency or program at issue for 
     the year for which the request is submitted, the Director 
     shall submit to the head of the applicable National Drug 
     Control Program Agency a written statement confirming the 
     adequacy of the request.
       ``(C) Record.--The Director shall maintain a record of each 
     description submitted under subparagraph (A) and each 
     statement submitted under subparagraph (B).
       ``(3) Specific requests.--The Director shall not confirm 
     the adequacy of any budget request that requests a level of 
     funding that will not enable achievement of the goals of the 
     National Drug Control Strategy, including--
       ``(A) requests funding for Federal law enforcement 
     activities that do not adequately compensate for transfers of 
     drug enforcement resources and personnel to law enforcement 
     and investigation activities;
       ``(B) requests funding for law enforcement activities on 
     the borders of the United States that do not adequately 
     direct resources to drug interdiction and enforcement;
       ``(C) requests funding for substance use disorder treatment 
     activities that do not provide adequate results and 
     accountability measures;
       ``(D) requests funding for substance use disorder treatment 
     activities that do not adequately support and enhance Federal 
     substance use disorder programs and capacity; and

[[Page H5307]]

       ``(E) requests funding for the operations and management of 
     the Department of Homeland Security that does not include a 
     specific request for funds for the Office of Counternarcotics 
     Enforcement to carry out its responsibilities under section 
     878 of the Homeland Security Act of 2002 (6 U.S.C. 458).
       ``(4) Agency response.--
       ``(A) In general.--The head of a National Drug Control 
     Program Agency that receives a description under paragraph 
     (2)(A) shall include the funding levels and initiatives 
     described by the Director in the budget submission for that 
     agency to the Office of Management and Budget.
       ``(B) Impact statement.--The head of a National Drug 
     Control Program Agency that has altered its budget submission 
     under this paragraph shall include as an appendix to the 
     budget submission for that agency to the Office of Management 
     and Budget an impact statement that summarizes--
       ``(i) the changes made to the budget under this paragraph; 
     and
       ``(ii) the impact of those changes on the ability of that 
     agency to perform its other responsibilities, including any 
     impact on specific missions or programs of the agency.
       ``(C) Congressional notification.--The head of a National 
     Drug Control Program Agency shall submit a copy of any impact 
     statement under subparagraph (B) to the Senate, the House of 
     Representatives, and the appropriate congressional 
     committees, at the time the budget for that agency is 
     submitted to Congress under section 1105(a).
       ``(5) Certification of budget submissions.--
       ``(A) In general.--At the time the head of a National Drug 
     Control Program Agency submits its budget request to the 
     Office of Management and Budget, the head of the National 
     Drug Control Program Agency shall submit a copy of the budget 
     request to the Director.
       ``(B) Review and certification of submissions.--The 
     Director shall review each budget submission submitted under 
     subparagraph (A) and submit to the appropriate congressional 
     committees one of the following:
       ``(i) A written certification of the budget submission for 
     the agency indicating such request fully funds the National 
     Drug Control Programs as necessary to achieve the goals of 
     the National Drug Control Strategy, including a written 
     statement explaining the basis for the determination that the 
     budget submission provides sufficient resources for the 
     agency to achieve the goals of the Strategy.
       ``(ii) A written certification of the budget submission for 
     the agency indicating such request partially funds the 
     National Drug Control Programs as necessary to achieve the 
     goals of the Strategy, including a written statement 
     explaining the basis for the determination to certify the 
     budget submission and identifying the level of funding 
     sufficient to achieve the goals of the Strategy.
       ``(iii) A written decertification of the budget submission 
     for the agency indicating the Director is unable to determine 
     whether such budget submission for the agency fully funds or 
     partially funds the National Drug Control Programs as 
     necessary to achieve the goals of the National Drug Control 
     Strategy, including a written statement identifying the 
     additional information necessary for the Director to make a 
     determination on such budget submission and the level of 
     funding sufficient to achieve the goals of the Strategy.
       ``(iv) A written decertification of the budget submission 
     for the agency indicating that such budget is insufficient to 
     fund the National Drug Control Programs as necessary to 
     achieve the goals of the Strategy, including a written 
     statement explaining the basis for the determination that the 
     budget is insufficient and identifying the level of funding 
     sufficient to achieve the goals of the Strategy.
       ``(d) National Drug Control Program Budget Proposal.--For 
     each fiscal year, following the transmission of proposed drug 
     control budget requests to the Director under subsection (b), 
     the Director shall, in consultation with the head of each 
     National Drug Control Program Agency and the head of each 
     major national organization that represents law enforcement 
     officers, agencies, or associations--
       ``(1) develop a consolidated National Drug Control Program 
     budget proposal designed to implement the National Drug 
     Control Strategy and to inform Congress and the public about 
     the total amount proposed to be spent on all supply 
     reduction, demand reduction, State, local, and Tribal 
     affairs, including any drug law enforcement, and other drug 
     control activities by the Federal Government, which shall 
     conform to the content requirements set forth in subsection 
     (b)(3) and include--
       ``(A) for each National Drug Control Program Agency, a list 
     of whether the funding level is full, partial, or 
     insufficient to achieve the goals of the National Drug 
     Control Strategy or whether the Director is unable to make 
     such determination;
       ``(B) a statement describing the extent to which any budget 
     of a National Drug Control Program Agency with less than full 
     funding hinders progress on achieving the goals of the 
     National Drug Control Strategy; and
       ``(C) alternative funding structures that could improve 
     progress on achieving the goals of the National Drug Control 
     Strategy; and
       ``(2) submit the consolidated budget proposal to the 
     President and Congress.
       ``(e) Budget Estimate or Request Submission to Congress.--
     Whenever the Director submits any budget estimate or request 
     to the President or the Office of Management and Budget, the 
     Director shall concurrently transmit to the appropriate 
     congressional committees a detailed statement of the 
     budgetary needs of the Office to execute its mission based on 
     the good-faith assessment of the Director.
       ``(f) Reprogramming and Transfer Requests.--
       ``(1) In general.--No National Drug Control Program Agency 
     shall submit to Congress a reprogramming or transfer request 
     with respect to any amount of appropriated funds in an amount 
     exceeding $1,000,000 that is included in the National Drug 
     Control Program budget unless the request has been approved 
     by the Director. If the Director has not responded to a 
     request for reprogramming subject to this paragraph within 30 
     days after receiving notice of the request having been made, 
     the request shall be deemed approved by the Director under 
     this paragraph and forwarded to Congress.
       ``(2) Appeal.--The head of any National Drug Control 
     Program Agency may appeal to the President any disapproval by 
     the Director of a reprogramming or transfer request under 
     this subsection.

     ``Sec. 1005. National drug control strategy

       ``(a) In General.--
       ``(1) Statement of drug policy priorities.--The Director 
     shall release a statement of drug control policy priorities 
     in the calendar year of a Presidential inauguration following 
     the inauguration but not later than April 1.
       ``(2) National drug control strategy submitted by the 
     president.--Not later than the first Monday in February 
     following the year in which the term of the President 
     commences, the President shall submit to Congress a National 
     Drug Control Strategy.
       ``(b) Development of the National Drug Control Strategy.--
       ``(1) Promulgation.--The Director shall promulgate the 
     National Drug Control Strategy, which shall set forth a 
     comprehensive plan to reduce illicit drug use and the 
     consequences of such illicit drug use in the United States by 
     limiting the availability of and reducing the demand for 
     illegal drugs and promoting prevention, early intervention, 
     treatment, and recovery support for individuals with 
     substance use disorders.
       ``(2) State and local commitment.--The Director shall seek 
     the support and commitment of State, local, and Tribal 
     officials in the formulation and implementation of the 
     National Drug Control Strategy.
       ``(3) Strategy based on evidence.--The Director shall 
     ensure the National Drug Control Strategy is based on the 
     best available medical and scientific evidence regarding the 
     policies that are most effective in reducing the demand for 
     and supply of illegal drugs.
       ``(4) Process for development and submission of national 
     drug control strategy.--In developing and effectively 
     implementing the National Drug Control Strategy, the 
     Director--
       ``(A) shall consult with--
       ``(i) the heads of the National Drug Control Program 
     Agencies;
       ``(ii) each Coordinator established under this chapter;
       ``(iii) the Interdiction Committee, the Treatment 
     Committee, and the Emerging Threats Task Force;
       ``(iv) the appropriate congressional committees and any 
     other committee of jurisdiction;
       ``(v) State, local, and Tribal officials;
       ``(vi) private citizens and organizations, including 
     community and faith-based organizations, with experience and 
     expertise in demand reduction;
       ``(vii) private citizens and organizations with experience 
     and expertise in supply reduction; and
       ``(viii) appropriate representatives of foreign 
     governments; and
       ``(B) in satisfying the requirements of subparagraph (A), 
     shall ensure, to the maximum extent possible, that State, 
     local, and Tribal officials and relevant private 
     organizations commit to support and take steps to achieve the 
     goals and objectives of the National Drug Control Strategy.
       ``(c) Contents of the National Drug Control Strategy.--
       ``(1) In general.--The National Drug Control Strategy 
     submitted under subsection (a)(2) shall include the 
     following:
       ``(A) A description of the current prevalence of illicit 
     drug use in the United States, including both the 
     availability of illicit drugs and the prevalence of substance 
     use disorders, which shall include the following:
       ``(i) Such description for the previous three years for any 
     drug identified as an emerging threat under section 1009 and 
     any other illicit drug identified by the Director as having a 
     significant impact on the prevalence of illicit drug use.
       ``(ii) A summary of the data and trends presented in the 
     Drug Control Data Dashboard required under section 1013.
       ``(B) A mission statement detailing the major functions of 
     the National Drug Control Program.
       ``(C) A list of comprehensive, research-based, long-range, 
     quantifiable goals for reducing illicit drug use, including--
       ``(i) the percentage of the total flow of illicit drugs to 
     be interdicted during the time period covered by the 
     Strategy; and
       ``(ii) the number of individuals to receive substance use 
     disorder treatment.

[[Page H5308]]

       ``(D) A description of how each goal established under 
     subparagraph (C) will be achieved, including for each goal--
       ``(i) a list of each relevant National Drug Control Program 
     Agency and each such agency's related programs, activities, 
     and available assets and the role of each such program, 
     activity, and asset in achieving such goal;
       ``(ii) a list of relevant stakeholders and each such 
     stakeholder's role in achieving such goal;
       ``(iii) an estimate of Federal funding and other resources 
     needed to achieve such goal;
       ``(iv) a list of each existing or new coordinating 
     mechanism needed to achieve such goal; and
       ``(v) a description of the Office's role in facilitating 
     the achievement of such goal.
       ``(E) For each year covered by the Strategy, a performance 
     evaluation plan for each goal established under subparagraph 
     (C) for each National Drug Control Program Agency, 
     including--
       ``(i) specific performance measures for each National Drug 
     Control Program Agency and each such agency's related 
     programs and activities;
       ``(ii) annual and, to the extent practicable, quarterly 
     objectives and targets for each performance measure; and
       ``(iii) an estimate of Federal funding and other resources 
     needed to achieve each performance objective and target.
       ``(F) A list identifying existing data sources or a 
     description of data collection needed to evaluate 
     performance, including a description of how the Director will 
     obtain such data.
       ``(G) A list of any anticipated challenges to achieving the 
     National Drug Control Strategy goals and planned actions to 
     address such challenges.
       ``(H) A description of how each goal established under 
     subparagraph (C) was determined, including--
       ``(i) a description of each required consultation and a 
     description of how such consultation was incorporated;
       ``(ii) data, research, or other information used to inform 
     the determination to establish the goal; and
       ``(iii) for any goal established under subparagraph (C)(i), 
     a statement of whether the goal will be adequate to disrupt 
     drug trafficking organizations that supply the majority of 
     foreign-sourced illicit drugs trafficked into the United 
     States.
       ``(I) A 5-year projection for program and budget 
     priorities.
       ``(J) A review of international, State, local, and private 
     sector drug control activities to ensure that the United 
     States pursues coordinated and effective drug control at all 
     levels of government.
       ``(K) Such statistical data and information as the Director 
     considers appropriate to demonstrate and assess trends 
     relating to illicit drug use, the effects and consequences of 
     illicit drug use (including the effects on children), supply 
     reduction, demand reduction, drug-related law enforcement, 
     and the implementation of the National Drug Control Strategy.
       ``(2) Additional strategies.--
       ``(A) In general.--The Director shall include in the 
     National Drug Control Strategy the additional strategies 
     described under this paragraph and shall comply with the 
     following:
       ``(i) Provide a copy of the additional strategies to the 
     appropriate congressional committees and to the Committee on 
     Armed Services and the Committee on Homeland Security of the 
     House of Representatives, and the Committee on Homeland 
     Security and Governmental Affairs and the Committee on Armed 
     Services of the Senate.
       ``(ii) Issue the additional strategies in consultation with 
     the head of each relevant National Drug Control Program 
     Agency, any relevant official of a State, local, or Tribal 
     government, and the government of other relevant countries.
       ``(iii) Not change any existing agency authority or 
     construe any strategy described under this paragraph to amend 
     or modify any law governing interagency relationship but may 
     include recommendations about changes to such authority or 
     law.
       ``(iv) Present separately from the rest of any strategy 
     described under this paragraph any information classified 
     under criteria established by an Executive order, or whose 
     public disclosure, as determined by the Director or the head 
     of any relevant National Drug Control Program Agency, would 
     be detrimental to the law enforcement or national security 
     activities of any Federal, State, local, or Tribal agency.
       ``(B) Requirement for southwest border counternarcotics.--
       ``(i) Purposes.--The Southwest Border Counternarcotics 
     Strategy shall--

       ``(I) set forth the Government's strategy for preventing 
     the illegal trafficking of drugs across the international 
     border between the United States and Mexico, including 
     through ports of entry and between ports of entry on that 
     border;
       ``(II) state the specific roles and responsibilities of the 
     relevant National Drug Control Program Agencies for 
     implementing that strategy; and
       ``(III) identify the specific resources required to enable 
     the relevant National Drug Control Program Agencies to 
     implement that strategy.

       ``(ii) Specific content related to drug tunnels between the 
     united states and mexico.--The Southwest Border 
     Counternarcotics Strategy shall include--

       ``(I) a strategy to end the construction and use of tunnels 
     and subterranean passages that cross the international border 
     between the United States and Mexico for the purpose of 
     illegal trafficking of drugs across such border; and
       ``(II) recommendations for criminal penalties for persons 
     who construct or use such a tunnel or subterranean passage 
     for such a purpose.

       ``(C) Requirement for northern border counternarcotics 
     strategy.--
       ``(i) Purposes.--The Northern Border Counternarcotics 
     Strategy shall--

       ``(I) set forth the strategy of the Federal Government for 
     preventing the illegal trafficking of drugs across the 
     international border between the United States and Canada, 
     including through ports of entry and between ports of entry 
     on the border;
       ``(II) state the specific roles and responsibilities of 
     each relevant National Drug Control Program Agency for 
     implementing the strategy;
       ``(III) identify the specific resources required to enable 
     the relevant National Drug Control Program Agencies to 
     implement the strategy;
       ``(IV) be designed to promote, and not hinder, legitimate 
     trade and travel; and
       ``(V) reflect the unique nature of small communities along 
     the international border between the United States and 
     Canada, ongoing cooperation and coordination with Canadian 
     law, enforcement authorities, and variations in the volumes 
     of vehicles and pedestrians crossing through ports of entry 
     along the international border between the United States and 
     Canada.

       ``(ii) Specific content related to cross-border indian 
     reservations.--The Northern Border Counternarcotics Strategy 
     shall include--

       ``(I) a strategy to end the illegal trafficking of drugs to 
     or through Indian reservations on or near the international 
     border between the United States and Canada; and
       ``(II) recommendations for additional assistance, if any, 
     needed by Tribal law enforcement agencies relating to the 
     strategy, including an evaluation of Federal technical and 
     financial assistance, infrastructure capacity building, and 
     interoperability deficiencies.

       ``(3) Classified information.--Any contents of the National 
     Drug Control Strategy that involve information properly 
     classified under criteria established by an Executive order 
     shall be presented to Congress separately from the rest of 
     the National Drug Control Strategy.
       ``(4) Selection of data and information.--In selecting data 
     and information for inclusion in the Strategy, the Director 
     shall ensure--
       ``(A) the inclusion of data and information that will 
     permit analysis of current trends against previously compiled 
     data and information where the Director believes such 
     analysis enhances long-term assessment of the National Drug 
     Control Strategy; and
       ``(B) the inclusion of data and information to permit a 
     standardized and uniform assessment of the effectiveness of 
     drug treatment programs in the United States.
       ``(d) Annual Performance Supplement.--Not later than the 
     first Monday in February of each year following the year in 
     which the National Drug Control Strategy is submitted 
     pursuant to subsection (a)(2), the Director shall submit to 
     the appropriate congressional committees a supplement to the 
     Strategy that shall include--
       ``(1) annual and, to the extent practicable, quarterly 
     quantifiable and measurable objectives and specific targets 
     to accomplish long-term quantifiable goals specified in the 
     Strategy; and
       ``(2) for each year covered by the Strategy, a performance 
     evaluation plan for each goal listed in the Strategy for each 
     National Drug Control Program Agency, including--
       ``(A) specific performance measures for each National Drug 
     Control Program Agency and each such agency's related 
     programs and activities;
       ``(B) annual and, to the extent practicable, quarterly 
     objectives and targets for each performance measure; and
       ``(C) an estimate of Federal funding and other resources 
     needed to achieve each performance objective and target.
       ``(e) Submission of Revised Strategy.--
       ``(1) In general.--The President may submit to Congress a 
     revised National Drug Control Strategy that meets the 
     requirements of this section--
       ``(A) at any time, upon a determination of the President, 
     in consultation with the Director, that the National Drug 
     Control Strategy in effect is not sufficiently effective; or
       ``(B) if a new President or Director takes office.
       ``(2) No submission .--In each year the President does not 
     submit a National Drug Control Strategy or a revised National 
     Drug Control Strategy, the Director shall evaluate the 
     efficacy and appropriateness of the goals of the National 
     Drug Control Strategy and include a statement affirming the 
     adequacy of the goals in the performance supplement under 
     subsection (d).
       ``(f) Failure of President to Submit National Drug Control 
     Strategy.--If the President does not submit a National Drug 
     Control Strategy to Congress in accordance with subsection 
     (a)(2), not later than five days after the first Monday in 
     February following the year in which the term of the 
     President commences, the President shall

[[Page H5309]]

     send a notification to the appropriate congressional 
     committees--
       ``(1) explaining why the Strategy was not submitted; and
       ``(2) specifying the date by which the Strategy will be 
     submitted.

     ``Sec. 1006. Development of an annual national drug control 
       assessment

       ``(a) Timing.--Not later than the first Monday in February 
     of each year, the Director shall submit to the President, 
     Congress, and the appropriate congressional committees, a 
     report assessing the progress of each National Drug Control 
     Program Agency toward achieving each goal, objective, and 
     target contained in the National Drug Control Strategy 
     applicable to the prior fiscal year.
       ``(b) Process for Development of the Annual Assessment.--
     Not later than November 1 of each year, the head of each 
     National Drug Control Program Agency shall submit, in 
     accordance with guidance issued by the Director, to the 
     Director an evaluation of progress by the agency with respect 
     to the National Drug Control Strategy goals using the 
     performance measures for the agency developed under this 
     chapter, including progress with respect to--
       ``(1) success in achieving the goals of the National Drug 
     Control Strategy;
       ``(2) success in reducing domestic and foreign sources of 
     illegal drugs;
       ``(3) success in expanding access to and increasing the 
     effectiveness of substance use disorder treatment;
       ``(4) success in protecting the borders of the United 
     States (and in particular the Southwestern border of the 
     United States) from penetration by illegal narcotics;
       ``(5) success in reducing crime associated with drug use in 
     the United States;
       ``(6) success in reducing the negative health and social 
     consequences of drug use in the United States; and
       ``(7) implementation of substance use disorder treatment 
     and prevention programs in the United States and improvements 
     in the adequacy and effectiveness of such programs.
       ``(c) Contents of the Annual Assessment.--The Director 
     shall include in the annual assessment required under 
     subsection (a)--
       ``(1) a summary of each evaluation received by the Director 
     under subsection (b);
       ``(2) a summary of the progress of each National Drug 
     Control Program Agency toward the National Drug Control 
     Strategy goals of the agency using the performance measures 
     for the agency developed under this chapter;
       ``(3) an assessment of the effectiveness of each National 
     Drug Control Program Agency and program in achieving the 
     National Drug Control Strategy for the previous year, 
     including a specific evaluation of whether the applicable 
     goals, measures, objectives, and targets for the previous 
     year were met;
       ``(4) for each National Drug Control Program Agency that 
     administers grant programs, an evaluation of the 
     effectiveness of each grant program, including an accounting 
     of the funds disbursed by the program in the prior year and a 
     summary of how those funds were used by the grantees and sub-
     grantees during that period;
       ``(5) a detailed accounting of the amount of funds 
     obligated by each National Drug Control Program Agency in 
     carrying out the responsibilities of that agency under the 
     Strategy;
       ``(6) an assessment of the effectiveness of any Emerging 
     Threat Response Plan in effect for the previous year, 
     including a specific evaluation of whether the objectives and 
     targets were met and reasons for the success or failure of 
     the previous year's plan;
       ``(7) a detailed accounting of the amount of funds 
     obligated during the previous fiscal year for carrying out 
     the campaign under section 1009(d), including each recipient 
     of funds, the purpose of each expenditure, the amount of each 
     expenditure, any available outcome information, and any other 
     information necessary to provide a complete accounting of the 
     funds expended; and
       ``(8) the assessments required under this subsection shall 
     be based on the Performance Measurement System describe in 
     subsection (d).
       ``(d) Performance Measurement System.--The Director shall 
     include in the annual assessment required under subsection 
     (a) a national drug control performance measurement system, 
     that--
       ``(1) develops annual, 2-year, and 5-year performance 
     measures, objectives, and targets for each National Drug 
     Control Strategy goal and objective established for reducing 
     drug use, availability, and the consequences of drug use;
       ``(2) describes the sources of information and data that 
     will be used for each performance measure incorporated into 
     the performance measurement system;
       ``(3) identifies major programs and activities of the 
     National Drug Control Program Agencies that support the goals 
     and annual objectives of the National Drug Control Strategy;
       ``(4) evaluates the contribution of demand reduction and 
     supply reduction activities implemented by each National Drug 
     Control Program Agency in support of the National Drug 
     Control Strategy;
       ``(5) monitors consistency between the drug-related goals, 
     measures, targets, and objectives of the National Drug 
     Control Program Agencies and ensures that each agency's goals 
     and budgets support, and are fully consistent with, the 
     National Drug Control Strategy; and
       ``(6) coordinates the development and implementation of 
     national drug control data collection and reporting systems 
     to support policy formulation and performance measurement, 
     including an assessment of--
       ``(A) the quality of current drug use measurement 
     instruments and techniques to measure supply reduction and 
     demand reduction activities;
       ``(B) the adequacy of the coverage of existing national 
     drug use measurement instruments and techniques to measure 
     the illicit drug user population and groups that are at risk 
     for illicit drug use;
       ``(C) the adequacy of the coverage of existing national 
     treatment outcome monitoring systems to measure the 
     effectiveness of substance use disorder treatment in reducing 
     illicit drug use and criminal behavior during and after the 
     completion of substance use disorder treatment; and
       ``(D) the actions the Director shall take to correct any 
     deficiencies and limitations identified pursuant to 
     subparagraphs (A), (B), and (C).
       ``(e) Modifications.--A description of any modifications 
     made during the preceding year to the national drug 
     performance measurement system described in subsection (d) 
     shall be included in each report submitted under subsection 
     (a).
       ``(f) Annual Report on Consultation.--The Director shall 
     include in the annual assessment required under subsection 
     (a)--
       ``(1) a detailed description of how the Office has 
     consulted with and assisted State, local, and Tribal 
     governments with respect to the formulation and 
     implementation of the National Drug Control Strategy and 
     other relevant issues; and
       ``(2) a general review of the status of, and trends in, 
     demand reduction activities by private sector entities and 
     community-based organizations, including faith-based 
     organizations, to determine their effectiveness and the 
     extent of cooperation, coordination, and mutual support 
     between such entities and organizations and Federal, State, 
     local, and Tribal government agencies.
       ``(g) Performance-budget Coordinator.--
       ``(1) Designation.--The Director shall designate or appoint 
     a United States Performance-Budget Coordinator to--
       ``(A) ensure the Director has sufficient information 
     necessary to analyze the performance of each National Drug 
     Control Program Agency, the impact Federal funding has had on 
     the goals in the Strategy, and the likely contributions to 
     the goals of the Strategy based on funding levels of each 
     National Drug Control Program Agency, to make an independent 
     assessment of the budget request of each agency under section 
     1004;
       ``(B) advise the Director on agency budgets, performance 
     measures and targets, and additional data and research needed 
     to make informed policy decisions under sections 1004 and 
     1005; and
       ``(C) other duties as may be determined by the Director 
     with respect to measuring or assessing performance or agency 
     budgets.
       ``(2) Determination of position.--The Director shall 
     determine whether the coordinator position is a noncareer 
     appointee in the Senior Executive Service or a career 
     appointee at the GS-15 level (or equivalent) or above.

     ``Sec. 1007. Monitoring and evaluation of national drug 
       control program

       ``(a) In General.--The Director shall monitor 
     implementation of the National Drug Control Program and the 
     activities of the National Drug Control Program Agencies in 
     carrying out the goals and objectives of the National Drug 
     Control Strategy including--
       ``(1) conducting program and performance audits and 
     evaluations; and
       ``(2) requesting assistance from the Inspector General of 
     the relevant agency in such audits and evaluations.
       ``(b) Accounting of Funds Expended.--(1) Not later than 
     February 1 of each year, in accordance with guidance issued 
     by the Director, the head of each National Drug Control 
     Program Agency shall submit to the Director a detailed 
     accounting of all funds expended by the agency for National 
     Drug Control Program activities during the previous fiscal 
     year and shall ensure such detailed accounting is 
     authenticated for the previous fiscal year by the Inspector 
     General for such agency prior to the submission to the 
     Director as frequently as determined by the Inspector General 
     but not less frequently that every three years.
       ``(2) The Director shall submit to Congress not later than 
     April 1 of each year the information submitted to the 
     Director under paragraph (1).
       ``(c) Notification.--The Director shall notify any National 
     Drug Control Program Agency if its activities are not in 
     compliance with the responsibilities of the agency under the 
     National Drug Control Strategy, transmit a copy of each such 
     notification to the President and the appropriate 
     congressional committees, and maintain a copy of each such 
     notification.
       ``(d) Recommendations.--The Director shall make such 
     recommendations to the President and the appropriate 
     congressional committees as the Director determines are 
     appropriate regarding changes in the organization, 
     management, and budgets of the National Drug Control Program 
     Agencies, and changes in the allocation of personnel to and 
     within those agencies, to implement the policies, goals, 
     objectives, and priorities established under section 
     1002(c)(1) and the National Drug Control Strategy.
       ``(e) Authorization, Development, and Implementation of a 
     Coordinated Tracking System.--

[[Page H5310]]

       ``(1) Establishment.--The Director shall establish a 
     coordinated tracking system of federally-funded initiatives 
     and grant programs which shall--
       ``(A) be the central repository of all drug control grants;
       ``(B) identify duplication, overlap, or gaps in funding to 
     provide increased accountability of federally-funded grants 
     for substance use disorder treatment, prevention, and 
     enforcement;
       ``(C) identify impediments that applicants currently have 
     in the grant application process with applicable agencies; 
     and
       ``(D) be developed and maintained by the Office with the 
     support of designated National Drug Control Program Agencies 
     and any other agency determined by the Director.
       ``(2) Performance metrics.--The Director shall identify 
     metrics and achievable goals for grant recipients in 
     furtherance of the Strategy. Such metrics shall be used to 
     measure how effective each federally funded initiative is in 
     achieving the objectives of the Strategy and to enable 
     comparisons of federally funded initiatives to identify those 
     that are the most cost effective.
       ``(3) Grant application standardization.--To reduce the 
     administrative burden on grant applicants and improve 
     oversight of Federal funds, the Director, in consultation 
     with the head of each National Drug Control Program Agency, 
     shall develop a plan for coordinating and standardizing drug 
     control grant application processes and develop a joint 
     application to be used by all National Drug Control Program 
     Agencies.
       ``(4) Central portal.--The Director shall maintain on the 
     public, electronic portal of the Office a list all drug 
     control grant programs available in a central location. The 
     head of each National Drug Control Program Agency shall 
     provide a complete list of all drug control program grant 
     programs to the Director and annually update such list.
       ``(5) Report to congress.--The Director shall include in 
     the assessment submitted to Congress under section 1006 an 
     assessment on progress under this section.

     ``Sec. 1008. Coordination and oversight of the national drug 
       control program

       ``(a) In General.--The Director shall coordinate and 
     oversee the implementation by the National Drug Control 
     Program Agencies of the policies, goals, objectives, and 
     priorities established under section 1002(c)(1) and the 
     fulfillment of the responsibilities of such agencies under 
     the National Drug Control Strategy and make recommendations 
     to National Drug Control Program Agency heads with respect to 
     implementation of National Drug Control Programs.
       ``(b) Detailing Employees to Other Agencies.--
       ``(1) Request.--The Director may request the head of an 
     agency or program of the Federal Government to place agency 
     personnel who are engaged in drug control activities on 
     temporary detail to another agency in order to implement the 
     National Drug Control Strategy.
       ``(2) Agency compliance.--The head of the agency shall 
     comply with any request made under paragraph (1).
       ``(3) Maximum number of detailees.--The maximum number of 
     personnel who may be detailed to another agency (including 
     the Office) under this subsection during any fiscal year is--
       ``(A) for the Department of Defense, 50; and
       ``(B) for any other agency, 10.
       ``(c) Directing Federal Funding.--The Director may transfer 
     funds made available to a National Drug Control Program 
     Agency for National Drug Control Strategy programs and 
     activities to another account within such agency or to 
     another National Drug Control Program Agency for National 
     Drug Control Strategy programs and activities, except that--
       ``(1) the authority under this subsection may be limited in 
     an annual appropriations Act or other provision of Federal 
     law;
       ``(2) the Director may exercise the authority under this 
     subsection only with the concurrence of the head of each 
     affected agency;
       ``(3) in the case of an interagency transfer, the total 
     amount of transfers under this subsection may not exceed 3 
     percent of the total amount of funds made available for 
     National Drug Control Strategy programs and activities to the 
     agency from which those funds are to be transferred;
       ``(4) funds transferred to an agency under this subsection 
     may only be used to increase the funding for programs or 
     activities authorized by law;
       ``(5) the Director shall--
       ``(A) submit to the appropriate congressional committees 
     and any other applicable committee of jurisdiction, a 
     reprogramming or transfer request in advance of any transfer 
     under this subsection in accordance with the regulations of 
     each affected agency; and
       ``(B) annually submit to the appropriate congressional 
     committees a report describing the effect of all transfers of 
     funds made pursuant to this subsection or section 1004(f) 
     during the 12-month period preceding the date on which the 
     report is submitted; and
       ``(6) funds may only be used for--
       ``(A) expansion of demand reduction activities;
       ``(B) interdiction of illicit drugs on the high seas, in 
     United States territorial waters, and at United States ports 
     of entry by officers and employees of National Drug Control 
     Program Agencies and domestic and foreign law enforcement 
     officers;
       ``(C) accurate assessment and monitoring of international 
     drug production and interdiction programs and policies;
       ``(D) activities to facilitate and enhance the sharing of 
     domestic and foreign intelligence information among National 
     Drug Control Program Agencies related to the production and 
     trafficking of drugs in the United States and foreign 
     countries;
       ``(E) activities to prevent the diversion of prescription 
     drugs for illicit use; and
       ``(F) research related to any of these activities.
       ``(d) Directing Federal Funding to Respond to Emerging 
     Threats.--
       ``(1) In general.--The Director may transfer funds made 
     available to a National Drug Control Program Agency for 
     National Drug Control Strategy programs and activities to 
     another account within such agency or to another National 
     Drug Control Program Agency for National Drug Control 
     Strategy programs and activities to implement the provisions 
     of a plan developed under section 1009, except that--
       ``(A) the authority under this subsection may be limited in 
     an annual appropriations Act or other provision of Federal 
     law;
       ``(B) the Director may exercise the authority under this 
     subsection only with the concurrence of the head of each 
     affected agency;
       ``(C) in the case of an interagency transfer, the total 
     amount of transfers under this subsection may not exceed 10 
     percent of the total amount of funds made available for 
     National Drug Control Strategy programs and activities to the 
     agency from which those funds are to be transferred;
       ``(D) funds transferred to an agency under this subsection 
     may only be used to increase the funding for programs or 
     activities authorized by law;
       ``(E) no transfer of funds under this subsection may result 
     in a reduction in total Federal expenditures for substance 
     use disorder treatment;
       ``(F) the Director shall--
       ``(i) submit to the appropriate congressional committees 
     and any other applicable committee of jurisdiction, a 
     reprogramming or transfer request in advance of any transfer 
     under this subsection in accordance with the regulations of 
     each affected agency; and
       ``(ii) annually submit to the appropriate congressional 
     committees a report describing the effect of all transfers of 
     funds made pursuant to this subsection or section 1004(f) 
     during the 12-month period preceding the date on which the 
     report is submitted; and
       ``(G) funds may only be used for--
       ``(i) expansion of demand reduction activities;
       ``(ii) interdiction of illicit drugs on the high seas, in 
     United States territorial waters, and at United States ports 
     of entry by officers and employees of National Drug Control 
     Program Agencies and domestic and foreign law enforcement 
     officers;
       ``(iii) accurate assessment and monitoring of international 
     drug production and interdiction programs and policies;
       ``(iv) activities to facilitate and enhance the sharing of 
     domestic and foreign intelligence information among National 
     Drug Control Program Agencies related to the production and 
     trafficking of drugs in the United States and foreign 
     countries;
       ``(v) activities to prevent the diversion of prescription 
     drugs for illicit use; and
       ``(vi) research related to any of these activities.
       ``(2) Inadequacy of transfer.--In the event the authority 
     under this subsection is inadequate to implement the 
     provisions of a plan developed under section 1009, the 
     Director shall submit a request for funding to the 
     appropriate congressional committees within 30 days after the 
     date on which the Director determines there is a need for 
     additional funding.
       ``(e) Fund Control Notices.--
       ``(1) In general.--The Director may issue to the head of a 
     National Drug Control Program Agency a fund control notice to 
     ensure compliance with the National Drug Control Program 
     Strategy. A fund control notice may direct that all or part 
     of an amount appropriated to the National Drug Control 
     Program Agency account be obligated by--
       ``(A) months, fiscal year quarters, or other time periods; 
     and
       ``(B) activities, functions, projects, or object classes.
       ``(2) Unauthorized obligation or expenditure prohibited.--
     An officer or employee of a National Drug Control Program 
     Agency shall not make or authorize an expenditure or 
     obligation contrary to a fund control notice issued by the 
     Director.
       ``(3) Disciplinary action for violation.--In the case of a 
     violation of paragraph (2) by an officer or employee of a 
     National Drug Control Program Agency, the head of the agency, 
     upon the request of and in consultation with the Director, 
     may subject the officer or employee to appropriate 
     administrative discipline, including, when circumstances 
     warrant, suspension from duty without pay or removal from 
     office.
       ``(4) Congressional notice.--Not later than 5 days after 
     issuance of a fund control notice, the Director shall submit 
     a copy of such fund control notice to the appropriate 
     congressional committees and make such notice publicly 
     available.
       ``(5) Restrictions.--The Director may not issue a fund 
     control notice to direct that all or part of an amount 
     appropriated to the National Drug Control Program Agency 
     account be obligated, modified, or altered in any manner 
     contrary, in whole or in part, to a specific appropriation or 
     statute.

[[Page H5311]]

       ``(f) Exclusions.--The authorities described under 
     subsections (c), (d), and (e) do not apply to any program 
     under subchapter II or III.
       ``(g) Foreign Assistance Act Participation.--The Director 
     may participate in the drug certification process pursuant to 
     section 490 of the Foreign Assistance Act of 1961 (22 U.S.C. 
     2291j) and section 706 of the Department of State 
     Authorization Act for Fiscal Year 2003 (22 U.S.C. 229j-l).
       ``(h) Certifications of Policy Changes to Director.--
       ``(1) In general.--Subject to paragraph (2), the head of a 
     National Drug Control Program Agency shall, unless exigent 
     circumstances require otherwise, notify the Director in 
     writing regarding any proposed change in policies relating to 
     the activities of that agency under the National Drug Control 
     Program prior to implementation of such change. The Director 
     shall promptly review such proposed change and certify to the 
     head of that agency in writing whether such change is 
     consistent with the National Drug Control Strategy.
       ``(2) Exception.--If prior notice of a proposed change 
     under paragraph (1) is not practicable--
       ``(A) the head of the National Drug Control Program Agency 
     shall notify the Director of the proposed change as soon as 
     practicable; and
       ``(B) upon such notification, the Director shall review the 
     change and certify to the head of that agency in writing 
     whether the change is consistent with the National Drug 
     Control Strategy.
       ``(i) Work in Conjunction With Assistant for National 
     Security Affairs.--The Director shall, in any matter 
     affecting national security interests, work in conjunction 
     with the Assistant to the President for National Security 
     Affairs.
       ``(j) Authorities Not Derogated.--Nothing in this chapter 
     shall be construed as derogating the authorities and 
     responsibilities of the head of any agency, the Director of 
     National Intelligence, or the Director of the Central 
     Intelligence Agency contained in the National Security Act of 
     1947 (50 U.S.C. 401 et seq.), the Central Intelligence Agency 
     Act of 1949 (50 U.S.C. 403a et seq.), or any other law.

     ``Sec. 1009. Emerging threats task force, plan, campaign

       ``(a) Emerging Threats Task Force.--
       ``(1) Emerging and continuing threats coordinator.--The 
     Director shall designate or appoint a United States Emerging 
     and Continuing Threats Coordinator to perform the duties of 
     that position described in this section and such other duties 
     as may be determined by the Director. The Director shall 
     determine whether the coordinator position is a noncareer 
     appointee in the Senior Executive Service or a career 
     appointee at the GS-15 level (or equivalent) or above.
       ``(2) Establishment and monitoring.--The Emerging and 
     Continuing Threats Coordinator (referred to in this section 
     as the `Coordinator') shall monitor evolving and emerging 
     drug threats in the United States and shall serve as Chair of 
     an Emerging Threats Task Force (in this section, referred to 
     as the `task force'). The Director shall appoint other 
     members of the task force, which shall include--
       ``(A) representatives from National Drug Control Program 
     Agencies or other agencies;
       ``(B) representatives from State, local, and Tribal 
     governments;
       ``(C) the Director of the National Drug Control Fusion 
     Center established in section 1013; and
       ``(D) representatives from other entities as determined to 
     be necessary by the Director.
       ``(3) Information review and sharing.--
       ``(A) In general.--The task force shall disseminate and 
     facilitate the sharing with Federal, State, local, and Tribal 
     officials and other entities as determined by the Director of 
     pertinent information and data relating to the following:
       ``(i) Recent trends in drug supply and demand.
       ``(ii) Fatal and nonfatal overdoses.
       ``(iii) Demand for and availability of evidence-based 
     substance use disorder treatment, including the extent of the 
     unmet treatment need, and treatment admission trends.
       ``(iv) Recent trends in drug interdiction, supply, and 
     demand from State, local, and Tribal law enforcement 
     agencies.
       ``(v) Other subject matter as determined necessary by the 
     Director.
       ``(B) Contract, agreement, and other authority.--The 
     Director may award contracts, enter into interagency 
     agreements, manage individual projects, and conduct other 
     activities in support of the identification of emerging drug 
     threats and in support of the development, implementation, 
     and assessment of any Emerging Threat Response Plan.
       ``(C) Data analysis activities.--In support of the task 
     force, the National Drug Control Fusion Center is authorized 
     to conduct and provide to the task force the results of data 
     analysis activities that the task force requests to aid in 
     their review of recent trends in the data disseminated under 
     subparagraph (A).
       ``(4) Criteria to identify emerging drug threats.--Not 
     later than 60 days after the date on which a task force first 
     meets, the task force shall develop and recommend to the 
     Director criteria to be used to identify an emerging drug 
     threat or the termination of an emerging drug threat 
     designation based on information gathered by the task force 
     in paragraph (2), statistical data, and other evidence.
       ``(5) Meetings.--The task force shall meet in person not 
     less frequently than quarterly and at additional meetings if 
     determined to be necessary by and at the call of the Chair 
     to--
       ``(A) identify and discuss evolving and emerging drug 
     trends in the United States using the criteria established in 
     paragraph (3);
       ``(B) assist in the formulation of any plan described in 
     subsection (c);
       ``(C) oversee implementation of the plan described in 
     subsection (c); and
       ``(D) provide such other advice to the Coordinator and 
     Director concerning strategy and policies for emerging drug 
     threats and trends as the task force determines to be 
     appropriate.
       ``(b) Designation.--
       ``(1) In general.--The Director, in consultation with the 
     Coordinator, the task force, and the head of each National 
     Drug Control Program Agency, may designate an emerging drug 
     threat in the United States.
       ``(2) Standards for designation.--The Director, in 
     consultation with the Coordinator, shall promulgate and make 
     publicly available standards by which a designation under 
     paragraph (1) and the termination of such designation may be 
     made. In developing such standards, the Director shall 
     consider the recommendations of the task force and other 
     criteria the Director considers to be appropriate.
       ``(3) Public statement required.--The Director shall 
     publish a public written statement on the portal of the 
     Office explaining the designation of an emerging drug threat 
     or the termination of such designation and shall notify the 
     appropriate congressional committees of the availability of 
     such statement when a designation or termination of such 
     designation has been made.
       ``(c) Plan.--
       ``(1) Public availability of plan.--Not later than 60 days 
     after making a designation under subsection (b), the Director 
     shall publish and make publicly available an Emerging Threat 
     Response Plan and notify the President and the appropriate 
     congressional committees of such plan's availability.
       ``(2) Timing.--Not less frequently than every 90 days after 
     the date on which the plan is published under paragraph (1), 
     the Director shall update the plan and report on 
     implementation of the plan, until the Director issues the 
     public statement required under subsection (b)(3) to 
     terminate the emerging drug threat designation.
       ``(3) Contents of an emerging threat response plan.--The 
     Director shall include in the plan--
       ``(A) a comprehensive strategic assessment of the emerging 
     drug threat, including the current availability of, demand 
     for, and effectiveness of evidence-based prevention, 
     treatment, and enforcement programs and efforts to respond to 
     the emerging drug threat;
       ``(B) comprehensive, research-based, long-range, 
     quantifiable goals for addressing the emerging drug threat, 
     including for reducing the supply of the drug designated as 
     the emerging drug threat and for expanding the availability 
     and effectiveness of evidence-based substance use disorder 
     treatment and prevention programs to reduce the demand for 
     the emerging drug threat;
       ``(C) performance measures pertaining to the plan's goals, 
     including quantifiable and measurable objectives and specific 
     targets;
       ``(D) the level of funding needed to implement the plan, 
     including whether funding is available to be reprogrammed or 
     transferred to support implementation of the plan or whether 
     additional appropriations are necessary to implement the 
     plan;
       ``(E) an implementation strategy for the education and 
     public awareness campaign under subsection (d), including 
     goals as described under subparagraph (B) and performance 
     measures, objectives, and targets, as described under 
     subparagraph (C); and
       ``(F) any other information necessary to inform the public 
     of the status, progress, or response of an emerging drug 
     threat.
       ``(4) Implementation.--
       ``(A) In general.--Not later than 90 days after the date on 
     which a designation is made under subsection (b), the 
     Director, in consultation with the President, the appropriate 
     congressional committees, and the head of each National Drug 
     Control Program Agency, shall issue guidance on 
     implementation of the plan described in this subsection to 
     the National Drug Control Program Agencies and any other 
     relevant agency determined to be necessary by the Director.
       ``(B) Coordinator's responsibilities.--The Coordinator 
     shall--
       ``(i) direct the implementation of the plan among the 
     agencies identified in the plan, State, local, and Tribal 
     governments, and other relevant entities;
       ``(ii) facilitate information-sharing between agencies 
     identified in the plan, State, local, and Tribal governments, 
     and other relevant entities; and
       ``(iii) monitor implementation of the plan by coordinating 
     the development and implementation of collection and 
     reporting systems to support performance measurement and 
     adherence to the plan by agencies identified in plan, where 
     appropriate.
       ``(C) Reporting.--Not later than 180 days after the date on 
     which a designation is made under subsection (b) and in 
     accordance

[[Page H5312]]

     with paragraph (2)(C), the head of each agency identified in 
     the plan shall submit to the Coordinator a report on 
     implementation of the plan.
       ``(d) Education and Public Awareness Campaign for Emerging 
     Drug Threats.--
       ``(1) In general.--Not later than 90 days after the date on 
     which a designation is made under subsection (b), the 
     Director shall, to the extent feasible and appropriate, 
     establish and implement an evidence-based substance use 
     prevention education and public awareness campaign to inform 
     the public about the dangers of any drug designated as an 
     emerging drug threat. Such campaign shall--
       ``(A) educate the public about the dangers of such drug, 
     including patient and family education about the 
     characteristics and hazards of such drug and methods to 
     safeguard against such dangers, including the safe disposal 
     of such drug;
       ``(B) support evidence-based prevention programs targeting 
     audiences' attitudes, perceptions, and beliefs concerning 
     substance use and intentions to initiate or continue such 
     use;
       ``(C) increase awareness of the negative consequences of 
     drug use;
       ``(D) encourage individuals affected by substance use 
     disorders to seek treatment and provide such individuals with 
     information on how to recognize addiction issues, what forms 
     of evidence-based treatment options are available, and how to 
     access such treatment; and
       ``(E) combat the stigma of addiction and substance use 
     disorders, including the stigma of treating such disorders 
     with medication-assisted treatment therapies.
       ``(2) Consultation.--For the planning of the campaign under 
     paragraph (1), the Director shall consult with--
       ``(A) the head of any appropriate National Drug Control 
     Program Agency to obtain advice on evidence-based scientific 
     information for policy, program development, and evaluation;
       ``(B) experts in evidence-based media campaigns, education, 
     evaluation, and communication;
       ``(C) experts on the designated drug;
       ``(D) State, local, and Tribal government officials and 
     relevant agencies;
       ``(E) the public;
       ``(F) appropriate congressional committees; and
       ``(G) any other affected person, as determined by the 
     Director.
       ``(3) Gifts and donations.--
       ``(A) In general.--The Director may accept gifts and 
     donations (in cash or in kind, including voluntary and 
     uncompensated services or property), which shall be available 
     until expended, for the purpose of supporting the education 
     and public awareness campaign authorized in this section, 
     including the media campaign.
       ``(B) Ethics guidelines.--The Director shall establish 
     written guidelines setting forth the criteria to be used in 
     determining whether a gift or donation should be declined 
     under this section because the acceptance of the gift or 
     donation would--
       ``(i) reflect unfavorably upon the ability of the Director 
     or the Office, or any employee of the Office, to carry out 
     responsibilities or official duties under this chapter in a 
     fair and objective manner; or
       ``(ii) compromise the integrity or the appearance of 
     integrity of programs or services provided under this chapter 
     or of any official involved in those programs or services.
       ``(4) Implementation.--
       ``(A) In general.--For any campaign established under this 
     subsection, the Director shall ensure the following:
       ``(i) Implementation is evidence-based, meets accepted 
     standards for public awareness campaigns, and uses available 
     resources in a manner to make the most progress toward 
     achieving the goals identified in the Emerging Threats 
     Response Plan and the requirements of paragraph (1).
       ``(ii) Information disseminated through the campaign is 
     accurate.
       ``(iii) The Director approves the strategy of the campaign, 
     all material distributed through the campaign, and the use of 
     any Federal funds used for the campaign.
       ``(iv) The campaign is designed using strategies found to 
     be most effective at achieving such goals and requirements of 
     paragraph (1), which may include--

       ``(I) a media campaign, as described in subparagraph (B);
       ``(II) local, regional, or population specific messaging;
       ``(III) establishing partnerships and promoting 
     coordination among community stakeholders, including public, 
     nonprofit organizations, and for profit entities;
       ``(IV) providing support, training, and technical 
     assistance to establish and expand school and community 
     prevention programs;
       ``(V) creating websites to publicize and disseminate 
     information;
       ``(VI) conducting outreach and providing educational 
     resources for parents;
       ``(VII) establishing State or regional advisory councils to 
     provide input and recommendations to raise awareness 
     regarding the drug designated as an emerging drug threat;
       ``(VIII) collaborating with law enforcement; and
       ``(IX) support for school-based public health education 
     classes to improve teen knowledge about the effects of such 
     designated drug.

       ``(B) Media campaign.--Any campaign implemented under this 
     subsection may include a media component, which--
       ``(i) shall be designed to prevent the use of the drug 
     designated as an emerging drug threat and to achieve the 
     goals and requirements of paragraph (1);
       ``(ii) shall be carried out through competitively awarded 
     contracts to entities providing for the professional 
     production and design of such campaign; and
       ``(iii) may include the use of television, radio, Internet, 
     social media, and other commercial marketing venues and may 
     be targeted to specific age groups based on peer-reviewed 
     social research.
       ``(C) Required notice for communication from the office.--
     Any communication, including an advertisement, paid for or 
     otherwise disseminated by the Office directly or through a 
     contract awarded by the Office shall include a prominent 
     notice informing the audience that the communication was paid 
     for by of the Office.
       ``(5) Evaluation.--
       ``(A) Performance evaluation.--The Director shall include 
     an evaluation of the campaign in the annual assessment under 
     section 1006, which shall include the following:
       ``(i) A performance evaluation of the campaign, including 
     progress toward meeting the goals, objectives, measures, and 
     targets identified in the Emerging Threats Response Plan.
       ``(ii) A description of all policies and practices to 
     eliminate the potential for waste, fraud, abuse, and to 
     ensure Federal funds are used responsibly.
       ``(iii) A list of all contracts or other agreements entered 
     into to implement the campaign.
       ``(iv) The results of any financial audit of the campaign.
       ``(v) A description of any evidence used to develop the 
     campaign.
       ``(vi) The sources and amount of each gift or donation 
     accepted by the Office, and the source and amount of each 
     gift or donation accepted by a contractor to be used in its 
     performance of a contract for the campaign.
       ``(B) Independent evaluation.--Not later than 180 days 
     after establishing a campaign under paragraph (1) and not 
     less than frequently than every two years thereafter, the 
     Director shall--
       ``(i) designate an independent entity to evaluate the 
     effectiveness of the campaign with meeting the goals 
     established in the Emerging Threat Response Plan and the 
     requirements of paragraph (1); and
       ``(ii) submit the results of the independent evaluation to 
     the appropriate congressional committees.
       ``(6) Funding prohibitions.--None of the amounts made 
     available under this subsection may be obligated for any of 
     the following:
       ``(A) To supplant current anti-drug community-based 
     coalitions.
       ``(B) To supplant pro bono public service time donated by 
     national and local broadcasting network for other public 
     services campaigns.
       ``(C) For partisan political purposes, or express advocacy 
     in support of or to defeat any clearly identified candidate, 
     clearly identified ballot initiative, or clearly identified 
     legislative or regulatory proposal.
       ``(D) For any advocacy in support of any particular 
     company, industry association, or advocacy group or the 
     explicit policy positions held by such groups.
       ``(E) To direct any individuals to a specific type of 
     substance use disorder treatment, treatment facility, medical 
     provider, or form of medication assisted treatment.
       ``(F) To fund any advertising that features any elected 
     officials, persons seeking elected office, cabinet level 
     officials, or other Federal officials employed pursuant to 
     section 213 of Schedule C of title 5, Code of Federal 
     Regulations.
       ``(e) Authorization of Appropriations.--There is authorized 
     to be appropriated to the Office to carry out this section, 
     $25,000,000 for each of fiscal years 2019 through 2023.

     ``Sec. 1010. National and international coordination

       ``(a) Dissemination of Research and Information to 
     States.--The Director shall ensure that drug control research 
     and information is effectively disseminated by National Drug 
     Control Program Agencies to State and local governments and 
     nongovernmental entities involved in demand reduction by--
       ``(1) encouraging formal consultation between any such 
     agency that conducts or sponsors research, and any such 
     agency that disseminates information in developing research 
     and information product development agendas;
       ``(2) encouraging such agencies (as appropriate) to develop 
     and implement dissemination plans that specifically target 
     State and local governments and nongovernmental entities 
     involved in demand reduction; and
       ``(3) supporting the substance abuse information 
     clearinghouse administered by the Assistant Secretary for 
     Mental Health and Substance Use and established in section 
     501(d)(16) of the Public Health Service Act by--
       ``(A) encouraging all National Drug Control Program 
     Agencies to provide all appropriate and relevant information; 
     and
       ``(B) supporting the dissemination of information to all 
     interested entities.
       ``(b) Standards.--
       ``(1) Development.--The Director shall coordinate the 
     development of evidence-based

[[Page H5313]]

     standards developed by National Drug Control Program Agencies 
     and other relevant agencies and non-Federal entities to 
     State, local, and Tribal governments and nongovernmental 
     entities related to drug control policies, practices, and 
     procedures, such as the investigation of drug-related deaths, 
     by--
       ``(A) encouraging appropriate agencies and State, local, 
     and Tribal governments to develop data standards for drug 
     control practices and procedures and related statistical 
     data;
       ``(B) encouraging information sharing between appropriate 
     agencies and State, local, and Tribal governments of relevant 
     drug control information and data;
       ``(C) establishing a working group of agencies, State, 
     local, and Tribal governments, and other relevant 
     stakeholders to discuss and develop such standards; and
       ``(D) facilitating collaboration among agencies, non-
     Federal entities, States, local, and Tribal governments, and 
     nongovernmental agencies.
       ``(2) Implementation.--The Director shall promote the 
     implementation of the standards described in paragraph (1) 
     by--
       ``(A) encouraging adoption by providing the standards to 
     State and local governments through the internet, annual 
     publications or periodicals, and other widely-disseminated 
     means; and
       ``(B) facilitating the use and dissemination of such 
     standards among State and local governments by--
       ``(i) providing technical assistance to State, local, and 
     Tribal governments seeking to adopt or implement such 
     standards; and
       ``(ii) coordinating seminars and training sessions for 
     State, local, and Tribal governments seeking to adopt or 
     implement such standards.
       ``(c) Private Sector.--
       ``(1) In general.--The Director or the head of a National 
     Drug Control Program (as designated by the Director) shall 
     coordinate with the private sector to promote private 
     research and development of medications to treat or prevent 
     addiction, including research and development for non-
     addictive pain management medication, abuse deterrent 
     formulations, medication-assisted treatment, and other 
     addiction research determined to be necessary by the Director 
     by--
       ``(A) encouraging the sharing of information regarding 
     evidence-based treatment addiction findings and related data 
     between agencies and the private sector, as appropriate;
       ``(B) encouraging collaboration between appropriate 
     agencies and the private sector; and
       ``(C) providing private sector entities with relevant 
     statistical data and information to enhance research as 
     permissible.
       ``(2) Working group.--The Director may establish a working 
     group of National Drug Control Program Agencies, State, 
     local, and Tribal governments, and the private sector 
     stakeholders to discuss and disseminate best practices, 
     research and development, and other related issues, as 
     appropriate.
       ``(d) Model Acts Program.--
       ``(1) In general.--The Director shall provide for or shall 
     enter into an agreement with a nonprofit organization to--
       ``(A) advise States on establishing laws and policies to 
     address illicit drug use issues; and
       ``(B) revise such model State drug laws and draft 
     supplementary model State laws to take into consideration 
     changes in illicit drug use issues in the State involved.
       ``(2) Authorization of appropriations.--There is authorized 
     to be appropriated to carry out this subsection $1,250,000 
     for each of fiscal years 2019 through 2023.
       ``(e) Drug Court Training and Technical Assistance 
     Program.--
       ``(1) Grants authorized.--The Director may make a grant to 
     a nonprofit organization for the purpose of providing 
     training and technical assistance to drug courts.
       ``(2) Authorization of appropriations.--There is authorized 
     to be appropriated to carry out this subsection $2,000,000 
     for each of fiscal years 2019 through 2023.
       ``(f) International Coordination.--The Director may 
     facilitate international drug control coordination efforts.
       ``(g) State, Local, and Tribal Affairs Coordinator.--The 
     Director shall designate or appoint a United States State, 
     Local, and Tribal Affairs Coordinator to perform the duties 
     of the Office outlined in this section and section 1005 and 
     such other duties as may be determined by the Director with 
     respect to coordination of drug control efforts between 
     agencies and State, local, and Tribal governments. The 
     Director shall determine whether the coordinator position is 
     a noncareer appointee in the Senior Executive Service or a 
     career appointee at the GS-15 level (or equivalent) or above.

     ``Sec. 1011. Interdiction

       ``(a) United States Interdiction Coordinator.--
       ``(1) In general.--The Director shall designate or appoint 
     a noncareer appointee in the Senior Executive Service or a 
     career appointee at the GS-15 level (or equivalent) or above 
     as the United States Interdiction Coordinator to perform the 
     duties of that position described in paragraph (2) and such 
     other duties as may be determined by the Director with 
     respect to coordination of efforts to interdict illicit drugs 
     from entering the United States.
       ``(2) Responsibilities.--The United States Interdiction 
     Coordinator shall be responsible to the Director for--
       ``(A) coordinating the interdiction activities of the 
     National Drug Control Program Agencies to ensure consistency 
     with the National Drug Control Strategy;
       ``(B) on behalf of the Director, developing and issuing, on 
     or before September 1 of each year and in accordance with 
     paragraph (4), a National Interdiction Command and Control 
     Plan to ensure the coordination and consistency described in 
     subparagraph (A);
       ``(C) assessing the sufficiency of assets committed to 
     illicit drug interdiction by the relevant National Drug 
     Control Program Agencies; and
       ``(D) advising the Director on the efforts of each National 
     Drug Control Program Agency to implement the National 
     Interdiction Command and Control Plan.
       ``(3) Staff.--The Director shall assign such permanent 
     staff of the Office as he considers appropriate to assist the 
     United States Interdiction Coordinator to carry out the 
     responsibilities described in paragraph (2), and may request 
     that appropriate National Drug Control Program Agencies 
     detail or assign staff to assist in carrying out such 
     activities.
       ``(4) National interdiction command and control plan.--
       ``(A) Purposes.--The National Interdiction Command and 
     Control Plan--
       ``(i) shall set forth the Government's strategy for drug 
     interdiction;
       ``(ii) shall state the specific roles and responsibilities 
     of the relevant National Drug Control Program Agencies for 
     implementing that strategy; and
       ``(iii) shall identify the specific resources required to 
     enable the relevant National Drug Control Program Agencies to 
     implement that strategy.
       ``(B) Consultation with other agencies.--Before the 
     submission of the National Drug Control Strategy or annual 
     supplement required under section 1005(d), as applicable, the 
     United States Interdiction Coordinator shall issue the 
     National Interdiction Command and Control Plan, in 
     consultation with the other members of the Interdiction 
     Committee described in subsection (b).
       ``(C) Report to congress.--On or before September 1 of each 
     year, the Director, through the United States Interdiction 
     Coordinator, shall provide to the appropriate congressional 
     committees, to the Committee on Armed Services and the 
     Committee on Homeland Security of the House of 
     Representatives, and to the Committee on Homeland Security 
     and Governmental Affairs and the Committee on Armed Services 
     of the Senate, a report that--
       ``(i) includes--

       ``(I) a copy of that year's National Interdiction Command 
     and Control Plan;
       ``(II) information for the previous 10 years regarding the 
     number and type of seizures of drugs by each National Drug 
     Control Program Agency conducting drug interdiction 
     activities and statistical information on the geographic 
     areas of such seizures; and
       ``(III) information for the previous 10 years regarding the 
     number of air and maritime patrol hours undertaken by each 
     National Drug Control Program Agency conducting drug 
     interdiction activities and statistical information on the 
     geographic areas in which such patrol hours took place; and

       ``(ii) may include recommendations about changes to 
     existing agency authorities or laws governing interagency 
     relationships.
       ``(D) Classified annex.--The report submitted pursuant to 
     subparagraph (C) may include a classified annex.
       ``(b) Interdiction Committee.--
       ``(1) In general.--The Interdiction Committee shall meet 
     to--
       ``(A) discuss and resolve issues related to the 
     coordination, oversight, and integration of international, 
     border, and domestic drug interdiction efforts in support of 
     the National Drug Control Strategy;
       ``(B) review the annual National Interdiction Command and 
     Control Plan, and provide advice to the Director and the 
     United States Interdiction Coordinator concerning that plan; 
     and
       ``(C) provide such other advice to the Director concerning 
     drug interdiction strategy and policies as the committee 
     determines is appropriate.
       ``(2) Chair.--The Director shall designate one of the 
     members of the Interdiction Committee to serve as Chair.
       ``(3) Meetings.--The members of the Interdiction Committee 
     shall meet, in person and not through any delegate or 
     representative, at least once per calendar year, before June 
     1. At the call of the Director or the Chair, the Interdiction 
     Committee may hold additional meetings, which shall be 
     attended by the members in person, or through such delegates 
     or representatives as the members may choose.
       ``(4) Report.--Not later than September 30 of each year, 
     the Chair of the Interdiction Committee shall submit to the 
     Director and to the appropriate congressional committees a 
     report describing the results of the meetings and any 
     significant findings of the committee during the previous 12 
     months. Such report may include a classified annex.

     ``Sec. 1012. Treatment coordinator

       ``(a) United States Treatment Coordinator.--
       ``(1) In general.--The Director shall designate or appoint 
     a noncareer appointee in the Senior Executive Service or a 
     career appointee at the GS-15 level (or equivalent) or above 
     as the United States Treatment Coordinator to perform the 
     responsibilities of that position described in paragraph (2) 
     and

[[Page H5314]]

     such other duties as may be determined by the Director with 
     respect to coordination of efforts to expand the availability 
     of substance use disorder treatment with the goal of 
     eliminating the unmet treatment need.
       ``(2) Responsibilities.--The United States Treatment 
     Coordinator shall be responsible to the Director for--
       ``(A) coordinating the activities of the National Drug 
     Control Program Agencies undertaken to expand the 
     availability of evidence-based substance use disorder 
     treatment to ensure consistency with the National Drug 
     Control Strategy;
       ``(B) on behalf of the Director, developing and issuing, on 
     or before September 1 of each year and in accordance with 
     paragraph (4), a National Treatment Plan to ensure the 
     coordination and consistency described in subparagraph (A);
       ``(C) assessing the sufficiency of Federal resources 
     directed to substance use disorder treatment by the relevant 
     National Drug Control Program Agencies;
       ``(D) encouraging the adoption by all substance use 
     disorder treatment providers of evidence-based standards to 
     guide all aspects of treatment provided; and
       ``(E) advising the Director on the efforts of each National 
     Drug Control Program Agency to implement the National 
     Treatment Plan.
       ``(3) Staff.--The Director shall assign such permanent 
     staff of the Office of the United States Treatment 
     Coordinator as the Director determines to be appropriate to 
     assist the United States Treatment Coordinator to carry out 
     the responsibilities described in paragraph (2), and may 
     request that appropriate National Drug Control Program 
     Agencies detail or assign staff to assist in carrying out 
     such responsibilities.
       ``(4) National treatment plan.--
       ``(A) Purposes.--The National Treatment Plan--
       ``(i) shall identify the unmet need for treatment for 
     evidence-based substance use disorders and set forth the 
     Government's strategy for closing the gap between available 
     and needed treatment through all sources;
       ``(ii) shall describe the specific roles and 
     responsibilities of the relevant National Drug Control 
     Program Agencies for implementing that strategy;
       ``(iii) shall identify the specific resources required to 
     enable the relevant National Drug Control Program Agencies to 
     implement that strategy;
       ``(iv) shall identify the resources, including private 
     sources, required to eliminate the unmet need for evidence-
     based substance use disorder treatment; and
       ``(v) may include recommendations about changes to existing 
     agency authorities or laws governing interagency 
     relationships.
       ``(B) Consultation with other agencies.--Before the 
     submission of the National Treatment Strategy or annual 
     supplement required under section 1005(d), as applicable, the 
     United States Treatment Coordinator shall issue the National 
     Treatment Plan, in consultation with the other members of the 
     Treatment Committee described in subsection (b).
       ``(C) Report to congress.--On or before September 1 of each 
     year, the Director, through the United States Treatment 
     Coordinator, shall provide to the appropriate congressional 
     committees a report that includes a copy of that year's 
     National Treatment Plan.
       ``(b) Treatment Committee.--
       ``(1) In general.--The Treatment Committee shall meet to--
       ``(A) review and discuss the adequacy of evidence-based 
     substance use disorder treatment as well as the unmet need 
     for treatment;
       ``(B) review and discuss the status of the implementation 
     of the National Treatment Plan; and
       ``(C) provide such other advice to the Director concerning 
     substance use disorder treatment initiatives as the committee 
     determines is appropriate.
       ``(2) Chair.--The Director shall designate one of the 
     members of the Treatment Committee to serve as Chair.
       ``(3) Meetings.--The members of the Treatment Committee 
     shall meet, in person and not through any delegate or 
     representative, at least once per calendar year, before June 
     1. At the call of the Director or the Chair, the Treatment 
     Committee may hold additional meetings, which shall be 
     attended by the members in person, or through such delegates 
     or representatives as the members may choose.
       ``(4) Report.--Not later than September 30 of each year, 
     the Chair of the Treatment Committee shall submit to the 
     Director and to the appropriate congressional committees a 
     report describing the results of the meetings and any 
     significant findings of the committee during the previous 12 
     months. Such report may include a classified annex.

     ``Sec. 1013. Critical information coordination

       ``(a) National Drug Control Fusion Center.--
       ``(1) Establishment.--The Director shall, in consultation 
     with the head of each National Drug Control Program Agency, 
     designate an agency to establish a National Drug Control 
     Fusion Center (referred to in this section as the `Center'). 
     The Center shall operate under the authority of the Director 
     and shall work with the National Drug Control Program 
     Agencies to collect, compile, analyze, and facilitate the 
     sharing of data on the use of illicit drugs, treatment for 
     substance use disorder, and interdiction of illicit drugs. 
     The Center shall be considered a `statistical agency or 
     unit', as that term is defined in section 502 of the 
     Confidential Information Protection and Statistical 
     Efficiency Act of 2002 (44 U.S.C. 3501 note) and shall have 
     the necessary independence to ensure any data or information 
     acquired by an agency under a pledge of confidentiality and 
     for exclusively statistical purposes is used exclusively for 
     statistical purposes.
       ``(2) Center director.--There shall be at the head of the 
     Center a Center Director who shall be appointed by the 
     Director from among individuals qualified and distinguished 
     in data governance and statistical analysis.
       ``(3) Data compilation.--The Director, acting through the 
     Center Director, shall do the following:
       ``(A) Coordinate data collection activities among the 
     National Drug Control Program Agencies.
       ``(B) Collect information not otherwise collected by 
     National Drug Control Program Agencies as necessary to inform 
     the National Drug Control Strategy.
       ``(C) Compile and analyze any data required to be collected 
     under this chapter.
       ``(D) Disseminate technology, as appropriate, to States and 
     local jurisdictions to enable or improve the collection of 
     data on drug use, including the recordation of the occurrence 
     of fatal and non-fatal drug overdoses.
       ``(E) Compile information collected by National Drug 
     Control Program Agencies on grants issued through any 
     National Drug Control Program, including for any grant the 
     following:
       ``(i) The recipient.
       ``(ii) The amount.
       ``(iii) The intended purpose.
       ``(iv) Any evidence of the efficacy of the outcomes 
     achieved by the program funded through the grant.
       ``(v) Any assessments of how the grant met its intended 
     purpose.
       ``(4) Toxicology screening.--
       ``(A) Establishment.--The Center Director may establish a 
     toxicology screening program that engages in--
       ``(i) secondary analysis of urine samples that would 
     otherwise be discarded by--

       ``(I) hospitals and substance use disorder treatment 
     programs;
       ``(II) correctional facilities, booking sites, probation 
     programs, drug courts, and related facilities; and
       ``(III) coroners and medical examiners; and

       ``(ii) analysis of other physical samples, as determined by 
     the Center Director to be valuable for understanding the 
     prevalence of any illicit drug.
       ``(B) De-identification of information.--The Center 
     Director shall ensure that no samples have any personally 
     identifiable information prior to collection.
       ``(C) Limitation on use.--No data obtained from analysis 
     conducted under this paragraph may be used as evidence in any 
     proceeding.
       ``(D) State program.--The Center Director may establish a 
     program that enables States and local jurisdictions to submit 
     up to 20 urine samples per year for toxicology analysis for 
     the purposes of identifying substances present in individuals 
     who have suffered fatal drug overdoses.
       ``(5) Authority to contract.--The Director may award 
     contracts, enter into interagency agreements, manage 
     individual projects, and conduct other operational activities 
     under this subsection.
       ``(b) Critical Drug Control Information and Evidence 
     Plan.--
       ``(1) In general.--Not later than the first Monday in 
     February of each year, the Director shall submit to Congress 
     a systematic plan for increasing data collection to enable 
     real-time surveillance of drug control threats, developing 
     analysis and monitoring capabilities, and identifying and 
     addressing policy questions relevant to the National Drug 
     Control Policy, Strategy, and Program. Such plan shall be 
     made available on the public online portal of the Office, 
     shall cover at least a 4-year period beginning with the first 
     fiscal year following the fiscal year in which the plan is 
     submitted and published, and contain the following:
       ``(A) A list of policy-relevant questions for which the 
     Director and each National Drug Control Program Agency 
     intends to develop evidence to support the National Drug 
     Control Program and Strategy.
       ``(B) A list of data the Director and each National Drug 
     Control Program Agency intends to collect, use, or acquire to 
     facilitate the use of evidence in drug control policymaking 
     and monitoring.
       ``(C) A list of methods and analytical approaches that may 
     be used to develop evidence to support the National Drug 
     Control Program and Strategy and related policy.
       ``(D) A list of any challenges to developing evidence to 
     support policymaking, including any barriers to accessing, 
     collecting, or using relevant data.
       ``(E) A description of the steps the Director and the head 
     of each National Drug Control Program Agency will take to 
     effectuate the plan.
       ``(F) Any other relevant information as determined by the 
     Director.
       ``(2) Consultation.--In developing the plan required under 
     paragraph (1), the Director shall consult with the following:
       ``(A) The public.
       ``(B) Any evaluation or analysis units and personnel of the 
     Office.

[[Page H5315]]

       ``(C) Office officials responsible for implementing privacy 
     policy.
       ``(D) Office officials responsible for data governance.
       ``(E) The appropriate congressional committees.
       ``(F) Any other individual or entity as determined by the 
     Director.
       ``(c) Evidence-based Policy.--
       ``(1) Harm reduction programs.--When developing the 
     national drug control policy, any policy of the Director, 
     including policies relating to syringe exchange programs for 
     intravenous drug users, shall be based on the best available 
     medical and scientific evidence regarding the effectiveness 
     of such policy in promoting individual health, preventing the 
     spread of infectious disease and the impact of such policy on 
     drug addiction and use. In making any policy relating to harm 
     reduction programs, the Director shall consult with the 
     National Institutes of Health and the National Academy of 
     Sciences.
       ``(2) Fund restriction for the legalization of controlled 
     substances.--The Director shall ensure that no Federal funds 
     appropriated to the Office shall be expended for any study or 
     contract relating to the legalization (for a medical use or 
     any other use) for which a listing in schedule I is in effect 
     under section 202 of the Controlled Substances Act (21 U.S.C. 
     812).
       ``(d) Drug Control Data Dashboard.--
       ``(1) Establishment.--The Director, in consultation with 
     the Center Director, shall establish and maintain a data 
     dashboard on the online portal of the Office to be known as 
     the `Drug Control Data Dashboard'. The Director shall ensure 
     the user interface of the dashboard is constructed with 
     modern design standards. To the extent practicable, the data 
     made available on the dashboard shall be publicly available 
     in a machine-readable format and searchable by year, agency, 
     drug, and location.
       ``(2) Data.--The data included in the Drug Control Data 
     Dashboard shall be updated quarterly to the extent 
     practicable, but not less frequently than annually and shall 
     include, at a minimum, the following:
       ``(A) For each substance identified under section 
     1005(c)(1)(A)(i)--
       ``(i) the total amount seized and disrupted in the calendar 
     year and each of the previous 3 calendar years, including to 
     the extent practicable the amount seized by State, local, and 
     Tribal governments;
       ``(ii) the known and estimated flows into the United States 
     from all sources in the calendar year and each of the 
     previous 3 calendar years;
       ``(iii) the total amount of known flows that could not be 
     interdicted or disrupted in the calendar year and each of the 
     previous 3 calendar years;
       ``(iv) the known and estimated levels of domestic 
     production in the calendar year and each of the previous 
     three calendar years, including the levels of domestic 
     production if the drug is a prescription drug, as determined 
     under the Federal Food, Drug, and Cosmetic Act, for which a 
     listing is in effect under section 202 of the Controlled 
     Substances Act (21 U.S.C. 812);
       ``(v) the average street price for the calendar year and 
     the highest known street price during the preceding 10-year 
     period; and
       ``(vi) to the extent practicable, related prosecutions by 
     State, local, and Tribal governments.
       ``(B) For the calendar year and each of the previous three 
     years data sufficient to show, disaggregated by State and, to 
     the extent feasible, by region within a State, county, or 
     city, the following:
       ``(i) The number of fatal and non-fatal overdoses caused by 
     each drug identified under subparagraph (A)(i).
       ``(ii) The prevalence of substance use disorders.
       ``(iii) The number of individuals who have received 
     substance use disorder treatment, including medication 
     assisted treatment, for a substance use disorder, including 
     treatment provided through publicly-financed health care 
     programs.
       ``(iv) The extent of the unmet need for substance use 
     disorder treatment, including the unmet need for medication-
     assisted treatment.
       ``(C) Data sufficient to show the extent of prescription 
     drug diversion, trafficking, and misuse in the calendar year 
     and each of the previous 3 calendar years.
       ``(D) Any quantifiable measures the Director determines to 
     be appropriate to detail progress toward the achievement of 
     the goals of the National Drug Control Strategy.
       ``(e) Access to Information.--
       ``(1) In general.--Upon the request of the Director, the 
     head of any National Drug Control Program Agency shall 
     cooperate with and provide to the Director any statistics, 
     studies, reports, and other information prepared or collected 
     by the agency concerning the responsibilities of the agency 
     under the National Drug Control Strategy that relate to--
       ``(A) drug control; or
       ``(B) the manner in which amounts made available to that 
     agency for drug control are being used by that agency.
       ``(2) Protection of intelligence information.--
       ``(A) In general.--The authorities conferred on the Office 
     and the Director by this chapter shall be exercised in a 
     manner consistent with provisions of the National Security 
     Act of 1947 (50 U.S.C. 401 et seq.). The Director of National 
     Intelligence shall prescribe such regulations as may be 
     necessary to protect information provided pursuant to this 
     chapter regarding intelligence sources and methods.
       ``(B) Duties of director.--The Director of National 
     Intelligence and the Director of the Central Intelligence 
     Agency shall, to the maximum extent practicable in accordance 
     with subparagraph (A), render full assistance and support to 
     the Office and the Director.
       ``(3) Required reports from national drug control program 
     agencies.--The head of each National Drug Control Program 
     Agency shall submit to the Director such information and 
     reports as requested from such National Drug Control Program 
     Agency by the Director, which shall include from the 
     appropriate National Drug Control Program Agencies:
       ``(A) Not later than July 1 of each year, the head of a 
     National Drug Control Program Agency designated by the 
     Director shall submit to the Director and the appropriate 
     congressional committees an assessment of the quantity of 
     illegal drug cultivation and manufacturing in the United 
     States on lands owned or under the jurisdiction of their 
     respective agencies that was seized or eradicated by their 
     personnel during the preceding calendar year.
       ``(B) Not later than July 1 of each year, the head of a 
     designated National Drug Control Program Agency shall submit 
     to the Director and the appropriate congressional committees 
     information for the preceding year regarding--
       ``(i) the number and type of seizures of drugs by each 
     component of the agency seizing drugs, as well as statistical 
     information on the geographic areas of such seizures; and
       ``(ii) the number of air and maritime patrol hours 
     primarily dedicated to drug supply reduction missions 
     undertaken by each component of the agency.
       ``(C) Not later than July 1 of each year, the head of a 
     designated National Drug Control Program Agency shall submit 
     to the Director and the appropriate congressional committees 
     information for the preceding year regarding the number of 
     air and maritime patrol hours primarily dedicated to drug 
     supply reduction missions undertaken by each component of the 
     agency.
       ``(D) Not later than July 1 of each year, the head of a 
     designated National Drug Control Program Agency shall submit 
     to the Director and the appropriate congressional committees 
     information for the preceding year regarding the number and 
     type of--
       ``(i) arrests for drug violations;
       ``(ii) prosecutions by United States Attorneys for drug 
     violations; and
       ``(iii) seizures of drugs by each component of the 
     Department of Justice seizing drugs, as well as statistical 
     information on the geographic areas of such seizures.
       ``(f) Data Exchange Standards for Improved 
     Interoperability.--
       ``(1) Interagency and intergovernmental designation and use 
     of data exchange standards working group.--The Director shall 
     establish a working group of National Drug Control Program 
     Agencies, State, local and Tribal government health and law 
     enforcement agencies, and data governance experts to develop 
     consensus data exchange standards for necessary categories of 
     information that allow effective electronic exchange of 
     information between States, between State agencies, between 
     States and National Drug Control Program Agencies, and any 
     other drug control relevant data exchange.
       ``(2) Data exchange standards must be nonproprietary and 
     interoperable.--The data exchange standards developed under 
     paragraph (1) shall, to the extent practicable, be 
     nonproprietary and interoperable.
       ``(3) Other requirements.--In developing data exchange 
     standards under this subsection, the working group shall, to 
     the extent practicable, incorporate--
       ``(A) interoperable standards developed and maintained by 
     an international voluntary consensus standards body, as 
     defined by the Office of Management and Budget;
       ``(B) interoperable standards developed and maintained by 
     intergovernmental partnerships; and
       ``(C) interoperable standards developed and maintained by 
     Federal entities with authority over contracting and 
     financial assistance.
       ``(4) Data exchange standards for federal reporting.--
       ``(A) Designation.--The Director may, in consultation with 
     the working group established under this subsection, National 
     Drug Control Program Agencies, and State, local, and Tribal 
     governments, designate data exchange standards to govern 
     Federal reporting and exchange requirements for National Drug 
     Control Programs, as appropriate.
       ``(B) Requirements.--The data exchange reporting standards 
     designated under subparagraph (A) shall, to the extent 
     practicable--
       ``(i) incorporate a widely accepted, nonproprietary, 
     searchable, machine-readable format;
       ``(ii) be consistent with and implement applicable 
     accounting principles;
       ``(iii) be implemented in a manner that is cost-effective 
     and improves program efficiency and effectiveness; and
       ``(iv) be capable of being continually upgraded as 
     necessary.
       ``(C) Incorporation of nonproprietary standards.--In 
     designating data exchange standards under this paragraph, the 
     Director

[[Page H5316]]

     shall, to the extent practicable, incorporate existing 
     nonproprietary standards.
       ``(D) Rule of construction.--Nothing in this paragraph 
     shall be construed to require a change to existing data 
     exchange standards for Federal reporting about a program 
     referred to in this section, if the head of the agency 
     responsible for administering the program finds the standards 
     to be effective and efficient.
       ``(5) Termination.--The working group established under 
     paragraph (1) shall terminate not earlier than 60 days after 
     the public notification of termination by the Director.
       ``(g) Annual Data Collection and Dissemination 
     Requirements.--
       ``(1) In general.--The Director shall collect and 
     disseminate, as appropriate, such information as the Director 
     determines is appropriate, but not less than the information 
     described in this subsection. To the extent practicable, the 
     data shall be publicly available in a machine-readable format 
     on the Drug Control Data Dashboard, be searchable by year, 
     agency, drug, and location, and cover not less than the 
     previous 10-year period.
       ``(2) Preparation and dissemination of information.--The 
     Director shall prepare and disseminate the following:
       ``(A) An assessment of current illicit drug use (including 
     inhalants and steroids) and availability, impact of illicit 
     drug use, and treatment availability, which assessment shall 
     include--
       ``(i) estimates of drug prevalence and frequency of use as 
     measured by national, State, and local surveys of illicit 
     drug use and by other special studies of nondependent and 
     dependent illicit drug use;
       ``(ii) illicit drug use in the workplace and the 
     productivity lost by such use; and
       ``(iii) illicit drug use by arrestees, probationers, and 
     parolees.
       ``(B) An assessment of the reduction of illicit drug 
     availability, for each drug identified under section 
     1005(c)(1)(A)(i), as measured by--
       ``(i) the quantities of such drug available for consumption 
     in the United States;
       ``(ii) the amount of such drug entering the United States;
       ``(iii) the number of illicit drug manufacturing 
     laboratories seized and destroyed of each such drug and the 
     number of hectares cultivated and destroyed domestically and 
     in other countries of such drug;
       ``(iv) the number of metric tons of such drug seized; and
       ``(v) changes in the price and purity of such drug.
       ``(C) An assessment of the reduction of the consequences of 
     illicit drug use and availability, which shall include--
       ``(i) the cost of treating substance use disorder in the 
     United States, such as the quantity of illicit drug-related 
     services provided;
       ``(ii) the annual national health care cost of illicit drug 
     use; and
       ``(iii) the extent of illicit drug-related crime and 
     criminal activity.
       ``(D) A determination of the status of substance use 
     disorder treatment in the United States, by assessing--
       ``(i) public and private treatment utilization; and
       ``(ii) the number of illicit drug users the Director 
     estimates meet diagnostic criteria for treatment.

     ``Sec. 1014. Authorization of appropriations

       ``There are authorized to be appropriated to carry out this 
     chapter, except as otherwise specified, to remain available 
     until expended, $18,400,000 for each of fiscal years 2019 
     through 2023.

         ``SUBCHAPTER II--DRUG-FREE COMMUNITIES SUPPORT PROGRAM

     ``Sec. 1021. Establishment of drug-free communities support 
       program

       ``(a) Establishment.--The Director shall establish a 
     program to support communities in the development and 
     implementation of comprehensive, long-term plans and programs 
     to prevent and treat substance use and misuse among youth.
       ``(b) Program.--In carrying out the Program, the Director 
     shall--
       ``(1) make and track grants to grant recipients;
       ``(2) provide for technical assistance and training, data 
     collection, and dissemination of information on state-of-the-
     art practices that the Director determines to be effective in 
     reducing substance use; and
       ``(3) provide for the general administration of the 
     Program.
       ``(c) Administration.--The Director shall appoint an 
     Administrator to carry out the Program.
       ``(d) Contracting.--The Director may employ any necessary 
     staff and may enter into contracts or agreements with 
     National Drug Control Program Agencies, including interagency 
     agreements, to delegate authority for the execution of grants 
     and for such other activities necessary to carry out this 
     chapter.

     ``Sec. 1022. Program authorization

       ``(a) Grant Eligibility.--To be eligible to receive an 
     initial grant or a renewal grant under this subchapter, a 
     coalition shall meet each of the following criteria:
       ``(1) Application.--The coalition shall submit an 
     application to the Administrator in accordance with section 
     1023(a)(2).
       ``(2) Major sector involvement.--
       ``(A) In general.--The coalition shall consist of 1 or more 
     representatives of each of the following categories:
       ``(i) Youth.
       ``(ii) Parents.
       ``(iii) Businesses.
       ``(iv) The media.
       ``(v) Schools.
       ``(vi) Organizations serving youth.
       ``(vii) Law enforcement.
       ``(viii) Religious or fraternal organizations.
       ``(ix) Civic and volunteer groups.
       ``(x) Health care professionals.
       ``(xi) State, local, or Tribal governmental agencies with 
     expertise in the field of substance use prevention or 
     substance use disorders (including, if applicable, the State 
     authority with primary authority for substance use and 
     misuse).
       ``(xii) Other organizations involved in reducing the 
     prevalence of substance use and misuse or substance use 
     disorders.
       ``(B) Elected officials.--If feasible, in addition to 
     representatives from the categories listed in subparagraph 
     (A), the coalition shall have an elected official (or a 
     representative of an elected official) from--
       ``(i) the Federal Government; and
       ``(ii) the government of the appropriate State and 
     political subdivision thereof or the governing body or an 
     Indian tribe (as that term is defined in section 4(e) of the 
     Indian Self-Determination Act (25 U.S.C. 5304)).
       ``(C) Representation.--An individual who is a member of the 
     coalition may serve on the coalition as a representative of 
     not more than 1 category listed under subparagraph (A).
       ``(3) Commitment.--The coalition shall demonstrate, to the 
     satisfaction of the Administrator--
       ``(A) that the representatives of the coalition have worked 
     together on substance use and misuse reduction initiatives, 
     which, at a minimum, includes initiatives that target drugs 
     described in section 1027(6)(A), for a period of not less 
     than 6 months, acting through entities such as task forces, 
     subcommittees, or community boards; and
       ``(B) substantial participation from volunteer leaders in 
     the community involved (especially in cooperation with 
     individuals involved with youth such as parents, teachers, 
     coaches, youth workers, and members of the clergy).
       ``(4) Mission and strategies.--The coalition shall, with 
     respect to the community involved--
       ``(A) have as its principal mission the reduction of 
     illegal drug use, which, at a minimum, includes the use of 
     illegal drugs described in section 1027(6)(A), in a 
     comprehensive and long-term manner, with a primary focus on 
     youth in the community;
       ``(B) describe and document the nature and extent of the 
     substance use and misuse problem, which, at a minimum, 
     includes the use and misuse of drugs described in section 
     1027(6)(A), in the community;
       ``(C)(i) provide a description of substance use and misuse 
     prevention and treatment programs and activities, which, at a 
     minimum, includes programs and activities relating to the use 
     and misuse of drugs described in section 1027(6)(A), in 
     existence at the time of the grant application; and
       ``(ii) identify substance use and misuse programs and 
     service gaps, which, at a minimum, includes programs and gaps 
     relating to the use and misuse of drugs described in section 
     1027(6)(A), in the community;
       ``(D) develop a strategic plan to reduce substance use and 
     misuse among youth, which, at a minimum, includes the use and 
     misuse of drugs described in section 1027(6)(A), in a 
     comprehensive and long-term fashion; and
       ``(E) work to develop a consensus regarding the priorities 
     of the community to combat substance use and misuse among 
     youth, which, at a minimum, includes the use and misuse of 
     drugs described in section 1027(6)(A).
       ``(5) Sustainability.--The coalition shall demonstrate that 
     the coalition is an ongoing concern by demonstrating that the 
     coalition--
       ``(A) is--
       ``(i)(I) a nonprofit organization; or
       ``(II) an entity that the Administrator determines to be 
     appropriate; or
       ``(ii) part of, or is associated with, an established legal 
     entity;
       ``(B) receives financial support (including, in the 
     discretion of the Administrator, in-kind contributions) from 
     non-Federal sources; and
       ``(C) has a strategy to solicit substantial financial 
     support from non-Federal sources to ensure that the coalition 
     and the programs operated by the coalition are self-
     sustaining.
       ``(6) Accountability.--The coalition shall--
       ``(A) establish a system to measure and report outcomes--
       ``(i) consistent with common indicators and evaluation 
     protocols established by the Administrator; and
       ``(ii) approved by the Administrator;
       ``(B) conduct--
       ``(i) for an initial grant under this subchapter, an 
     initial benchmark survey of drug use among youth (or use 
     local surveys or performance measures available or accessible 
     in the community at the time of the grant application); and
       ``(ii) biennial surveys (or incorporate local surveys in 
     existence at the time of the evaluation) to measure the 
     progress and effectiveness of the coalition; and
       ``(C) provide assurances that the entity conducting an 
     evaluation under this paragraph, or from which the coalition 
     receives information, has experience--

[[Page H5317]]

       ``(i) in gathering data related to substance use and misuse 
     among youth; or
       ``(ii) in evaluating the effectiveness of community anti-
     drug coalitions.
       ``(7) Additional criteria.--The Director shall not impose 
     any eligibility criteria on new applicants or renewal 
     grantees not provided in this chapter.
       ``(b) Grant Amounts.--
       ``(1) In general.--
       ``(A) Grants.--
       ``(i) In general.--Subject to clause (iv), for a fiscal 
     year, the Administrator may grant to an eligible coalition 
     under this paragraph, an amount not to exceed the amount of 
     non-Federal funds raised by the coalition, including in-kind 
     contributions, for that fiscal year.
       ``(ii) Suspension of grants.--If such grant recipient fails 
     to continue to meet the criteria specified in subsection (a), 
     the Administrator may suspend the grant, after providing 
     written notice to the grant recipient and an opportunity to 
     appeal.
       ``(iii) Renewal grants.--Subject to clause (iv), the 
     Administrator may award a renewal grant to a grant recipient 
     under this subparagraph for each fiscal year following the 
     fiscal year for which an initial grant is awarded, in an 
     amount not to exceed the amount of non-Federal funds raised 
     by the coalition, including in-kind contributions, for that 
     fiscal year, during the 4-year period following the period of 
     the initial grant.
       ``(iv) Limitation.--The amount of a grant award under this 
     subparagraph may not exceed $125,000 for a fiscal year.
       ``(B) Coalition awards.--
       ``(i) In general.--Except as provided in clause (ii), the 
     Administrator may, with respect to a community, make a grant 
     to 1 eligible coalition that represents that community.
       ``(ii) Exception.--The Administrator may make a grant to 
     more than 1 eligible coalition that represents a community 
     if--

       ``(I) the eligible coalitions demonstrate that the 
     coalitions are collaborating with one another; and
       ``(II) each of the coalitions has independently met the 
     requirements set forth in subsection (a).

       ``(2) Rural coalition grants.--
       ``(A) In general.--
       ``(i) In general.--In addition to awarding grants under 
     paragraph (1), to stimulate the development of coalitions in 
     sparsely populated and rural areas, the Administrator may 
     award a grant in accordance with this section to a coalition 
     that represents a county with a population that does not 
     exceed 30,000 individuals. In awarding a grant under this 
     paragraph, the Administrator may waive any requirement under 
     subsection (a) if the Administrator considers that waiver to 
     be appropriate.
       ``(ii) Matching requirement.--Subject to subparagraph (C), 
     for a fiscal year, the Administrator may grant to an eligible 
     coalition under this paragraph, an amount not to exceed the 
     amount of non-Federal funds raised by the coalition, 
     including in-kind contributions, for that fiscal year.
       ``(iii) Suspension of grants.--If such grant recipient 
     fails to continue to meet any criteria specified in 
     subsection (a) that has not been waived by the Administrator 
     pursuant to clause (i), the Administrator may suspend the 
     grant, after providing written notice to the grant recipient 
     and an opportunity to appeal.
       ``(B) Renewal grants.--The Administrator may award a 
     renewal grant to an eligible coalition that is a grant 
     recipient under this paragraph for each fiscal year following 
     the fiscal year for which an initial grant is awarded, in an 
     amount not to exceed the amount of non-Federal funds raised 
     by the coalition, including in-kind contributions, during the 
     4-year period following the period of the initial grant.
       ``(C) Limitations.--
       ``(i) Amount.--The amount of a grant award under this 
     paragraph shall not exceed $125,000 for a fiscal year.
       ``(ii) Awards.--With respect to a county referred to in 
     subparagraph (A), the Administrator may award a grant under 
     this section to not more than 1 eligible coalition that 
     represents the county.
       ``(3) Additional grants.--
       ``(A) In general.--Subject to subparagraph (F), the 
     Administrator may award an additional grant under this 
     paragraph to an eligible coalition awarded a grant under 
     paragraph (1) or (2) for any first fiscal year after the end 
     of the 4-year period following the period of the initial 
     grant under paragraph (1) or (2), as the case may be.
       ``(B) Scope of grants.--A coalition awarded a grant under 
     paragraph (1) or (2), including a renewal grant under such 
     paragraph, may not be awarded another grant under such 
     paragraph, and is eligible for an additional grant under this 
     section only under this paragraph.
       ``(C) No priority for applications.--The Administrator may 
     not afford a higher priority in the award of an additional 
     grant under this paragraph than the Administrator would 
     afford the applicant for the grant if the applicant were 
     submitting an application for an initial grant under 
     paragraph (1) or (2) rather than an application for a grant 
     under this paragraph.
       ``(D) Renewal grants.--Subject to subparagraph (F), the 
     Administrator may award a renewal grant to a grant recipient 
     under this paragraph for each of the fiscal years of the 4-
     fiscal-year period following the fiscal year for which the 
     initial additional grant under subparagraph (A) is awarded in 
     an amount not to exceed amounts as follows:
       ``(i) For the first and second fiscal years of that 4-
     fiscal-year period, the amount of the non-Federal funds, 
     including in-kind contributions, raised by the coalition for 
     the applicable fiscal year is not less than 125 percent of 
     the amount awarded.
       ``(ii) For the third and fourth fiscal years of that 4-
     fiscal-year period, the amount of the non-Federal funds, 
     including in-kind contributions, raised by the coalition for 
     the applicable fiscal year is not less than 150 percent of 
     the amount awarded.
       ``(E) Suspension.--If a grant recipient under this 
     paragraph fails to continue to meet the criteria specified in 
     subsection (a), the Administrator may suspend the grant, 
     after providing written notice to the grant recipient and an 
     opportunity to appeal.
       ``(F) Limitation.--The amount of a grant award under this 
     paragraph may not exceed $125,000 for a fiscal year.
       ``(4) Process for suspension.--A grantee shall not be 
     suspended or terminated under paragraph (1)(A)(ii), 
     (2)(A)(iii), or (3)(E) unless that grantee is afforded a 
     fair, timely, and independent appeal prior to such suspension 
     or termination.
       ``(c) Treatment of Funds for Coalitions Representing 
     Certain Organizations.--Funds appropriated for the substance 
     use and misuse activities of a coalition that includes a 
     representative of the Bureau of Indian Affairs, the Indian 
     Health Service, or a Tribal government agency with expertise 
     in the field of substance use prevention may be counted as 
     non-Federal funds raised by the coalition for purposes of 
     this section.
       ``(d) Priority in Awarding Grants.--In awarding grants 
     under subsection (b)(1)(A)(i), priority shall be given to a 
     coalition serving economically disadvantaged areas.

     ``Sec. 1023. Information collection and dissemination with 
       respect to grant recipients

       ``(a) Coalition Information.--
       ``(1) General auditing authority.--For the purpose of audit 
     and examination, the Administrator--
       ``(A) shall have access to any books, documents, papers, 
     and records that are pertinent to any grant or grant renewal 
     request under this subchapter; and
       ``(B) may periodically request information from a grant 
     recipient to ensure that the grant recipient meets the 
     applicable criteria under section 1022(a).
       ``(2) Application process.--The Administrator shall issue a 
     request for proposal regarding, with respect to the grants 
     awarded under section 1022, the application process, grant 
     renewal, and suspension or withholding of renewal grants. 
     Each application under this paragraph shall be in writing and 
     shall be subject to review by the Administrator.
       ``(3) Reporting.--The Administrator shall, to the maximum 
     extent practicable and in a manner consistent with applicable 
     law, minimize reporting requirements by a grant recipient and 
     expedite any application for a renewal grant made under this 
     subchapter.
       ``(b) Data Collection and Dissemination.--
       ``(1) In general.--The Administrator may collect data 
     from--
       ``(A) national substance use and misuse organizations that 
     work with eligible coalitions, community anti-drug 
     coalitions, departments or agencies of the Federal 
     Government, or State or local governments and the governing 
     bodies of Indian Tribes; and
       ``(B) any other entity or organization that carries out 
     activities that relate to the purposes of the Program.
       ``(2) Activities of administrator.--The Administrator may--
       ``(A) evaluate the utility of specific initiatives relating 
     to the purposes of the Program;
       ``(B) conduct an evaluation of the Program; and
       ``(C) disseminate information described in this subsection 
     to--
       ``(i) eligible coalitions and other substance use 
     prevention organizations; and
       ``(ii) the general public.
       ``(3) Consultation.--The Administrator shall carry out 
     activities under this subsection in consultation with the 
     National Community Antidrug Coalition Institute.
       ``(4) Limitation on use of certain funds for evaluation of 
     program.--Amounts for activities under paragraph (2)(B) may 
     not be derived from amounts under section 1028(a) except for 
     amounts that are available under section 1028(b) for 
     administrative costs.

     ``Sec. 1024. Technical assistance and training

       ``(a) In General.--
       ``(1) Technical assistance and agreements.--With respect to 
     any grant recipient or other organization, the Administrator 
     may--
       ``(A) offer technical assistance and training; and
       ``(B) enter into contracts and cooperative agreements.
       ``(2) Coordination of programs.--The Administrator may 
     facilitate the coordination of programs between a grant 
     recipient and other organizations and entities.
       ``(b) Training.--The Administrator may provide training to 
     any representative designated by a grant recipient in--
       ``(1) coalition building;
       ``(2) task force development;
       ``(3) mediation and facilitation, direct service, 
     assessment and evaluation; or
       ``(4) any other activity related to the purposes of the 
     Program.

[[Page H5318]]

  


     ``Sec. 1025. Supplemental grants for coalition mentoring 
       activities

       ``(a) Authority to Make Grants.--As part of the Program, 
     the Director may award an initial grant under this 
     subsection, and renewal grants under subsection (f), to any 
     coalition awarded a grant under section 1022 that meets the 
     criteria specified in subsection (d) in order to fund 
     coalition mentoring activities by such coalition in support 
     of the program.
       ``(b) Treatment With Other Grants.--
       ``(1) Supplement.--A grant awarded to a coalition under 
     this section is in addition to any grant awarded to the 
     coalition under section 1022.
       ``(2) Requirement for basic grant.--A coalition may not be 
     awarded a grant under this section for a fiscal year unless 
     the coalition was awarded a grant or renewal grant under 
     section 1022(b) for that fiscal year.
       ``(c) Application.--A coalition seeking a grant under this 
     section shall submit to the Administrator an application for 
     the grant in such form and manner as the Administrator may 
     require.
       ``(d) Criteria.--A coalition meets the criteria specified 
     in this subsection if the coalition--
       ``(1) has been in existence for at least 5 years;
       ``(2) has achieved, by or through its own efforts, 
     measurable results in the prevention and treatment of 
     substance use and misuse among youth;
       ``(3) has staff or members willing to serve as mentors for 
     persons seeking to start or expand the activities of other 
     coalitions in the prevention and treatment of substance use 
     and misuse;
       ``(4) has demonstrable support from some members of the 
     community in which the coalition mentoring activities to be 
     supported by the grant under this section are to be carried 
     out; and
       ``(5) submits to the Administrator a detailed plan for the 
     coalition mentoring activities to be supported by the grant 
     under this section.
       ``(e) Use of Grant Funds.--A coalition awarded a grant 
     under this section shall use the grant amount for mentoring 
     activities to support and encourage the development of new, 
     self-supporting community coalitions that are focused on the 
     prevention and treatment of substance use and misuse in such 
     new coalitions' communities. The mentoring coalition shall 
     encourage such development in accordance with the plan 
     submitted by the mentoring coalition under subsection (d)(5).
       ``(f) Renewal Grants.--The Administrator may make a renewal 
     grant to any coalition awarded a grant under subsection (a), 
     or a previous renewal grant under this subsection, if the 
     coalition, at the time of application for such renewal 
     grant--
       ``(1) continues to meet the criteria specified in 
     subsection (d); and
       ``(2) has made demonstrable progress in the development of 
     one or more new, self-supporting community coalitions that 
     are focused on the prevention and treatment of substance use 
     and misuse.
       ``(g) Grant Amounts.--
       ``(1) In general.--Subject to paragraphs (2) and (3), the 
     total amount of grants awarded to a coalition under this 
     section for a fiscal year may not exceed the amount of non-
     Federal funds raised by the coalition, including in-kind 
     contributions, for that fiscal year. Funds appropriated for 
     the substance use and misuse activities of a coalition that 
     includes a representative of the Bureau of Indian Affairs, 
     the Indian Health Service, or a Tribal government agency with 
     expertise in the field of substance use prevention may be 
     counted as non-Federal funds raised by the coalition.
       ``(2) Initial grants.--The amount of the initial grant 
     awarded to a coalition under subsection (a) may not exceed 
     $75,000.
       ``(3) Renewal grants.--The total amount of renewal grants 
     awarded to a coalition under subsection (f) for any fiscal 
     year may not exceed $75,000.
       ``(h) Fiscal Year Limitation on Amount Available for 
     Grants.--The total amount available for grants under this 
     section, including renewal grants under subsection (f), in 
     any fiscal year may not exceed the amount equal to five 
     percent of the amount authorized to be appropriated by 
     section 1028 for that fiscal year.
       ``(i) Priority in Awarding Initial Grants.--In awarding 
     initial grants under this section, priority shall be given to 
     a coalition that expressly proposes to provide mentorship to 
     a coalition or aspiring coalition serving economically 
     disadvantaged areas.

     ``Sec. 1026. Authorization for National Community Antidrug 
       Coalition Institute

       ``(a) In General.--The Director shall, using amounts 
     authorized to be appropriated by subsection (d), make a 
     competitive grant to provide for the continuation of the 
     National Community Anti-drug Coalition Institute.
       ``(b) Eligible Organizations.--An organization eligible for 
     the grant under subsection (a) is any national nonprofit 
     organization that represents, provides technical assistance 
     and training to, and has special expertise and broad, 
     national-level experience in community antidrug coalitions 
     under this subchapter.
       ``(c) Use of Grant Amount.--The organization that receives 
     the grant under subsection (a) shall continue a National 
     Community Anti-Drug Coalition Institute to--
       ``(1) provide education, training, and technical assistance 
     for coalition leaders and community teams, with emphasis on 
     the development of coalitions serving economically 
     disadvantaged areas;
       ``(2) develop and disseminate evaluation tools, mechanisms, 
     and measures to better assess and document coalition 
     performance measures and outcomes; and
       ``(3) bridge the gap between research and practice by 
     translating knowledge from research into practical 
     information.
       ``(d) Authorization of Appropriations.--The Director shall, 
     using amounts authorized to be appropriated by section 1028, 
     make a grant of $2,000,000 under subsection (a), for each of 
     the fiscal years 2019 through 2023.

     ``Sec. 1027. Definitions

       ``In this subchapter:
       ``(1) Administrator.--The term `Administrator' means the 
     Administrator appointed by the Director under section 
     1021(c).
       ``(2) Community.--The term `community' shall have the 
     meaning provided that term by the Administrator.
       ``(3) Eligible coalition.--The term `eligible coalition' 
     means a coalition that meets the applicable criteria under 
     section 1022(a).
       ``(4) Grant recipient.--The term `grant recipient' means 
     the recipient of a grant award under section 1022.
       ``(5) Program.--The term `Program' means the program 
     established under section 1021(a).
       ``(6) Substance use and misuse.--The term `substance use 
     and misuse' means--
       ``(A) the illegal use or misuse of drugs, including 
     substances for which a listing is in effect under any of 
     schedules I through V under section 202 of the Controlled 
     Substances Act (21 U.S.C. 812);
       ``(B) the misuse of inhalants or over the counter drugs; or
       ``(C) the use of alcohol, tobacco, or other related product 
     as such use is prohibited by State or local law.
       ``(7) Youth.--The term `youth' shall have the meaning 
     provided that term by the Administrator.

     ``Sec. 1028. Drug-free communities reauthorization

       ``(a) Authorization of Appropriations.--There are 
     authorized to be appropriated to the Office to carry out this 
     subchapter $99,000,000 for each of the fiscal years 2019 
     through 2023.
       ``(b) Administrative Costs.--Not more than 8 percent of the 
     funds appropriated for this subchapter may be used by the 
     Office or, in the discretion of the Director, an agency 
     delegated to carry out the program under section 1021(d) to 
     pay for administrative costs associated with carrying out the 
     program.''.
       (d) Technical and Conforming Amendment.--The table of 
     chapters for subtitle I of title 31, United States Code, is 
     amended by adding at the end the following new item:

``10. Office of National Drug Control.......................1001''.....

     SEC. 3. HIGH INTENSITY DRUG TRAFFICKING AREAS PROGRAM.

       (a) Establishment.--
       (1) In general.--There is established in the Office a 
     program to be known as the High Intensity Drug Trafficking 
     Areas Program (in this section referred to as the 
     ``Program'').
       (2) Purpose.--The purpose of the Program is to reduce drug 
     trafficking and drug production in the United States by--
       (A) facilitating cooperation among Federal, State, local, 
     and Tribal law enforcement agencies to share information and 
     implement coordinated enforcement activities;
       (B) enhancing law enforcement intelligence sharing among 
     Federal, State, local, and Tribal law enforcement agencies;
       (C) providing reliable law enforcement intelligence to law 
     enforcement agencies needed to design effective enforcement 
     strategies and operations; and
       (D) supporting coordinated law enforcement strategies which 
     maximize use of available resources to reduce the supply of 
     illegal drugs in designated areas and in the United States as 
     a whole.
       (b) Designation.--
       (1) In general.--The Director, in consultation with the 
     Attorney General, the Secretary of the Treasury, the 
     Secretary of Homeland Security, the head of each National 
     Drug Control Program Agency, and the Governor of each 
     applicable State, may designate any specified area of the 
     United States as a high intensity drug trafficking area.
       (2) Activities.--After making a designation under paragraph 
     (1) and in order to provide Federal assistance to the area so 
     designated, the Director may--
       (A) obligate such sums as are appropriated for the Program;
       (B) direct the temporary reassignment of Federal personnel 
     to such area, subject to the approval of the head of the 
     agency that employs such personnel;
       (C) take any other action authorized under this section or 
     chapter 10 of title 31, United States Code, as added by 
     section 2(c), to provide increased Federal assistance to 
     those areas; and
       (D) coordinate activities under this section (specifically 
     administrative, recordkeeping, and funds management 
     activities) with State, local, and Tribal officials.
       (c) Petitions for Designation.--The Director shall 
     establish and maintain regulations under which a coalition of 
     interested law enforcement agencies from an area may petition 
     for designation as a high intensity drug trafficking area (in 
     this section referred

[[Page H5319]]

     to as the ``HIDTA''). Such regulations shall provide for a 
     regular review by the Director of the petition, including a 
     recommendation regarding the merit of the petition to the 
     Director by a panel of qualified, independent experts.
       (d) Factors for Consideration.--In considering whether to 
     designate an area under this section as a high intensity drug 
     trafficking area, the Director shall consider, in addition to 
     such other criteria as the Director considers to be 
     appropriate, the extent to which--
       (1) the area is a significant center of illegal drug 
     production, manufacturing, importation, or distribution;
       (2) State, local, and Tribal law enforcement agencies have 
     committed resources to respond to the drug trafficking 
     problem in the area, thereby indicating a determination to 
     respond aggressively to the problem;
       (3) drug-related activities in the area are having a 
     significant harmful impact in the area, and in other areas of 
     the country; and
       (4) a significant increase in allocation of Federal 
     resources is necessary to respond adequately to drug-related 
     activities in the area.
       (e) Organization of High Intensity Drug Trafficking 
     Areas.--
       (1) Executive board and officers.--To be eligible for funds 
     appropriated under this section, each high intensity drug 
     trafficking area shall be governed by an Executive Board. The 
     Executive Board shall designate a chairman, vice chairman, 
     and any other officers to the Executive Board that it 
     determines are necessary.
       (2) Responsibilities.--The Executive Board of a high 
     intensity drug trafficking area shall be responsible for--
       (A) providing direction and oversight in establishing and 
     achieving the goals of the high intensity drug trafficking 
     area;
       (B) managing the funds of the high intensity drug 
     trafficking area;
       (C) reviewing and approving all funding proposals 
     consistent with the overall objective of the high intensity 
     drug trafficking area; and
       (D) reviewing and approving all reports to the Director on 
     the activities of the high intensity drug trafficking area.
       (3) Board representation.--None of the funds appropriated 
     under this section may be expended for any high intensity 
     drug trafficking area, or for a partnership or region of a 
     high intensity drug trafficking area, if the Executive Board 
     for such area, region, or partnership, does not apportion an 
     equal number of votes between representatives of 
     participating agencies and representatives of participating 
     State, local, and Tribal agencies. Where it is impractical 
     for an equal number of representatives of agencies and State, 
     local, and Tribal agencies to attend a meeting of an 
     Executive Board in person, the Executive Board may use a 
     system of proxy votes or weighted votes to achieve the voting 
     balance required by this paragraph.
       (4) No agency relationship.--The eligibility requirements 
     of this section are intended to ensure the responsible use of 
     Federal funds. Nothing in this section is intended to create 
     an agency relationship between individual high intensity drug 
     trafficking areas and the Federal Government.
       (f) Use of Funds.--The Director shall ensure that not more 
     than 5 percent of Federal funds appropriated for the Program 
     are expended for substance use disorder treatment programs 
     and not more than 5 percent of the Federal funds appropriated 
     for the Program are expended for drug prevention programs.
       (g) Counterterrorism Activities.--
       (1) Assistance authorized.--The Director may authorize use 
     of resources available for the Program to assist Federal, 
     State, local, and Tribal law enforcement agencies in 
     investigations and activities related to terrorism and 
     prevention of terrorism, especially but not exclusively with 
     respect to such investigations and activities that are also 
     related to drug trafficking.
       (2) Limitation.--The Director shall ensure--
       (A) that assistance provided under paragraph (1) remains 
     incidental to the purpose of the Program to reduce drug 
     availability and carry out drug-related law enforcement 
     activities; and
       (B) that significant resources of the Program are not 
     redirected to activities exclusively related to terrorism, 
     except on a temporary basis under extraordinary 
     circumstances, as determined by the Director.
       (h) Role of Drug Enforcement Administration.--The Director, 
     in consultation with the Attorney General, shall ensure that 
     a representative of the Drug Enforcement Administration is 
     included in the Intelligence Support Center for each high 
     intensity drug trafficking area.
       (i) Emerging Threat Response Fund.--
       (1) In general.--Subject to the availability of 
     appropriations, the Director may expend up to 10 percent of 
     the amounts appropriated under this section on a 
     discretionary basis, in accordance with the criteria 
     established under paragraph (2)--
       (A) to respond to any emerging drug trafficking threat in 
     an existing high intensity drug trafficking area;
       (B) to establish a new high intensity drug trafficking 
     area; or
       (C) to expand an existing high intensity drug trafficking 
     area.
       (2) Consideration of impact.--In allocating funds under 
     this subsection, the Director shall consider--
       (A) the impact of activities funded on reducing overall 
     drug traffic in the United States, or minimizing the 
     probability that an emerging drug trafficking threat will 
     spread to other areas of the United States; and
       (B) such other criteria as the Director considers 
     appropriate.
       (j) Annual Hidta Program Budget Submissions.--As part of 
     the documentation that supports the President's annual budget 
     request for the Office, the Director shall submit to Congress 
     a budget justification that includes--
       (1) the amount proposed for each HIDTA, conditional upon a 
     review by the Office of the request submitted by such HIDTA 
     and the performance of such HIDTA, with supporting narrative 
     descriptions and rationale for each request;
       (2) a detailed justification that explains--
       (A) the reasons for the proposed funding level and how such 
     funding level was determined based on a current assessment of 
     the drug trafficking threat in each high intensity drug 
     trafficking area;
       (B) how such funding will ensure that the goals and 
     objectives of each such area will be achieved; and
       (C) how such funding supports the National Drug Control 
     Strategy; and
       (3) the amount of HIDTA funds used to investigate and 
     prosecute organizations and individuals trafficking in each 
     major illicit drug, as identified by the Director, in the 
     prior calendar year, and a description of how those funds 
     were used.
       (k) Hidta Annual Evaluation Report.--As part of each report 
     submitted pursuant to section 1006(a) of title 31, United 
     States Code, as added by section 2(c), the Director shall 
     include, for each designated high intensity drug trafficking 
     area, a report that--
       (1) describes--
       (A) the specific purposes for the high intensity drug 
     trafficking area; and
       (B) the specific long-term and short-term goals and 
     objectives for the high intensity drug trafficking area;
       (2) includes an evaluation of the performance of the high 
     intensity drug trafficking area in accomplishing the specific 
     long-term and short-term goals and objectives identified 
     under subparagraph (1)(B);
       (3) assesses the number and operation of all federally 
     funded drug enforcement task forces within such high 
     intensity drug trafficking area;
       (4) describes--
       (A) each Federal, State, local, and Tribal drug enforcement 
     task force operating in such high intensity drug trafficking 
     area;
       (B) how such task forces coordinate with each other, with 
     any high intensity drug trafficking area task force, and with 
     investigations receiving funds from the Organized Crime and 
     Drug Enforcement Task Force;
       (C) what steps, if any, each such task force takes to share 
     information regarding drug trafficking and drug production 
     with other federally funded drug enforcement task forces in 
     the high intensity drug trafficking area;
       (D) the role of the high intensity drug trafficking area in 
     coordinating the sharing of such information among task 
     forces;
       (E) the nature and extent of cooperation by each Federal, 
     State, local, and Tribal participant in ensuring that such 
     information is shared among law enforcement agencies and with 
     the high intensity drug trafficking area;
       (F) the nature and extent to which information sharing and 
     enforcement activities are coordinated with joint terrorism 
     task forces in the high intensity drug trafficking area; and
       (G) any recommendations for measures needed to ensure that 
     task force resources are utilized efficiently and effectively 
     to reduce the availability of illegal drugs in the high 
     intensity drug trafficking areas; and
       (5) in consultation with the Director of National 
     Intelligence--
       (A) evaluates existing and planned law enforcement 
     intelligence systems supported by such high intensity drug 
     trafficking area, or utilized by task forces receiving any 
     funding under the Program, including the extent to which such 
     systems ensure access and availability of law enforcement 
     intelligence to Federal, State, local, and Tribal law 
     enforcement agencies within the high intensity drug 
     trafficking area and outside of such area;
       (B) evaluates the extent to which Federal, State, local, 
     and Tribal law enforcement agencies participating in each 
     high intensity drug trafficking area are sharing law 
     enforcement intelligence information to assess current drug 
     trafficking threats and design appropriate enforcement 
     strategies; and
       (C) identifies the measures needed to improve effective 
     sharing of information and law enforcement intelligence 
     regarding drug trafficking and drug production among Federal, 
     State, local, and Tribal law enforcement participating in a 
     high intensity drug trafficking area, and between such 
     agencies and similar agencies outside the high intensity drug 
     trafficking area.
       (l) Coordination of Law Enforcement Intelligence Sharing 
     With Organized Crime Drug Enforcement Task Force Program.--
       (1) Drug enforcement intelligence sharing.--The Director, 
     in consultation with the Attorney General, shall ensure that 
     any drug enforcement intelligence obtained by the 
     Intelligence Support Center for each high intensity drug 
     trafficking area is shared, on a timely basis, with the drug 
     intelligence fusion center operated by the Organized Crime 
     Drug Enforcement Task Force of the Department of Justice.

[[Page H5320]]

       (2) Certification.--Before the Director awards any funds to 
     a high intensity drug trafficking area, the Director shall 
     certify that the law enforcement entities participating in 
     that HIDTA are providing laboratory seizure data to the 
     national clandestine laboratory database at the El Paso 
     Intelligence Center.
       (m) Authorization of Appropriations.--There is authorized 
     to be appropriated to the Office to carry out this section 
     $280,000,000 for each fiscal years 2019 through 2023.
       (n) Specific Purposes.--
       (1) In general.--The Director shall ensure that, of the 
     amounts appropriated for a fiscal year for the Program, at 
     least 2.5 percent is used in high intensity drug trafficking 
     areas with severe neighborhood safety and illegal drug 
     distribution problems.
       (2) Required uses.--The funds used under paragraph (1) 
     shall be used to ensure the safety of neighborhoods and the 
     protection of communities, including the prevention of the 
     intimidation of witnesses of illegal drug distribution and 
     related activities and the establishment of or support for 
     programs that provide protection or assistance to witnesses 
     in court proceedings.
       (3) Best practice models.--The Director shall work with the 
     HIDTAs to develop and maintain best practice models to assist 
     State, local, and Tribal governments in addressing witness 
     safety, relocation, financial and housing assistance, or any 
     other services related to witness protection or assistance in 
     cases of illegal drug distribution and related activities. 
     The Director shall ensure dissemination of the best practice 
     models to each HIDTA.

     SEC. 4. OPIOID CRISIS RESPONSE.

       (a) Emerging Threat Designation.--The Director shall 
     designate opioids and opioid analogues as emerging drug 
     threats, in accordance with section 1009 of title 31, United 
     States Code, as added by section 2(c).
       (b) Opioid Response Plan.--
       (1) Issuance.--Not later than 60 days after the date of the 
     enactment of this Act, the Director shall publish, make 
     publicly available, and notify the President and the 
     appropriate congressional committees of, the plan required 
     under section 1009 of title 31, United States Code, as added 
     by section 2(c), to be designated as the ``National Opioid 
     Crisis Response Plan''.
       (2) Contents.--The Director shall ensure the plan 
     establishes measurable goals, including reducing fatal and 
     non-fatal overdoses, and includes the following:
       (A) An initiative to ensure the United States mail is 
     effectively screened to prevent illicit drugs from entering 
     the United States, including--
       (i) designating the United States Postal Service as a 
     National Drug Control Program Agency;
       (ii) directing the United States Postal Service and any 
     other related National Drug Control Program Agency to take 
     any appropriate actions necessary to reduce the amount of 
     illicit drugs entering the country; and
       (iii) developing an international coordination plan, in 
     consultation with the National Drug Control Program Agencies 
     and in accordance with section 1010 of such title 31, United 
     States Code, as added by section 2(c), to include efforts to 
     address international drug control initiatives and strengthen 
     bilateral and multilateral strategies to reduce illicit drugs 
     and precursor chemicals from entering the United States 
     through international mail or across land borders or ports of 
     entry.
       (B) Support for universal adoption of evidence-based 
     prescribing guidelines, including--
       (i) establishing a task force to supplement existing 
     prescribing guidelines with evidence-based standards and to 
     facilitate, coordinate, and, as appropriate, conduct research 
     to inform such guidelines;
       (ii) encouraging the adoption of evidence-based prescribing 
     guidelines by each relevant agency, State and local 
     governments, and private sector organizations;
       (iii) issuing guidance to National Drug Control Program 
     Agencies to, as appropriate, revise regulations to ensure 
     professionals have effective continuing education 
     requirements; and
       (iv) disseminating and encouraging the adoption of best 
     practices and evidence-based guidelines for effective 
     prescribing practices.
       (C) A program to monitor the prescription drug market and 
     illicit drug market for changes in trends relevant to 
     reducing the supply or demand of such drugs.
       (D) An initiative to facilitate and coordinate Federal, 
     State and local government initiatives, studies, and pilot or 
     demonstration programs designed to evaluate the benefits of 
     drug courts and related programs that reduce substance use 
     prevalence.
       (E) A program, developed in coordination with the private 
     sector, to--
       (i) facilitate the development of treatment and abuse-
     deterrent products, in accordance with section 1010(c) of 
     title 31, United States Code, as added by section 2(c); and
       (ii) encourage the expansion of medication disposal 
     programs and technology.
       (F) Initiatives to--
       (i) encourage the National Drug Control Program Agencies 
     and the program established under section 1010(d) of title 
     31, United States Code, as added by section 2(c), to 
     prioritize the development of sentencing standards or model 
     codes for trafficking opioids and opioid analogues; and
       (ii) to advise States on establishing laws and policies to 
     address opioid issues based on the recommendations developed 
     and set forth by the President's Commission on Combating Drug 
     Addiction and the Opioid Crisis.
       (G) A program to identify successful college recovery 
     programs, including sober housing programs that provide a 
     shared living residence free of alcohol or illicit drug use 
     for individuals recovering from drug or alcohol addiction and 
     substance use disorders, on college campuses and disseminate 
     best practices to Colleges and Universities to increase the 
     number and capacity of such programs.
       (H) Convening working groups, consisting of the appropriate 
     National Drug Control Program Agencies, State, local and 
     Tribal governments, and other appropriate stakeholders, 
     established in accordance with section 1010 of title 31, 
     United States Code, as added by section 2(c)--
       (i) to support Prescription Drug Monitoring Programs by--

       (I) facilitating the sharing and interoperability of 
     program data among States and Federal prescription drug 
     monitoring programs;
       (II) assisting States in increasing utilization of such 
     programs;
       (III) facilitating efforts to incorporate available 
     overdose and naloxone deployment data into such programs;
       (IV) evaluating barriers to integrating program data with 
     electronic health records; and
       (V) offering recommendations to address identified 
     barriers; and

       (ii) to develop standards, and encourage the use of such 
     standards, for the collection of data necessary to understand 
     and monitor the opioid crisis, including--

       (I) State medical examiner reports on deaths caused by 
     overdoses and related statistical data; and
       (II) first responder opioid intoxication incidents.

       (I) Research initiatives, to be initiated not later than 30 
     days after the issuance of the plan, to evaluate the uses and 
     barriers to use of and the effects of improving the following 
     programs:
       (i) Medication Assisted Treatment.
       (ii) Data collection systems used to confirm opioid use by 
     individuals who have been arrested or hospitalized.
       (J) A requirement for an Advisory Committee on Substance 
     Use Disorder Treatment Standards, to be established not later 
     than 120 days after the issuance of the plan, to promulgate 
     model evidence-based standards for substance use disorder 
     treatment and recovery facilities which--
       (i) shall be chaired by the Director;
       (ii) shall include as members of the advisory committee 
     representatives of the relevant National Drug Control Program 
     Agencies;
       (iii) may include as members of the advisory committee 
     government regulators, State representatives, consumer 
     representatives, substance use disorder treatment providers, 
     recovery residence owners and operators, and purchasers of 
     substance use disorder treatments; and
       (iv) shall ensure such model standards are promulgated no 
     later than 2 years after the date of the issuance of the 
     plan.
       (c) Recommendations.--Not later than 1 year after the date 
     of the enactment of this Act, the Director shall submit to 
     the appropriate congressional committees a report on the 
     results of the initiatives conducted under subsection 
     (b)(2)(I) and may include recommendations based on such 
     results.
       (d) Grant Report to Congress.--Not later than 1 year after 
     the date of the enactment of this Act, the Director shall 
     submit to the appropriate congressional committees an 
     assessment on the feasibility of block grants of Federal 
     funding to States.

     SEC. 5. EXCEPTIONS AND RULES OF CONSTRUCTION.

       (a) Inapplicability to Certain Programs.--This Act, and the 
     amendments made by this Act, shall not apply to the National 
     Intelligence Program and the Military Intelligence Program, 
     unless such program or an element of such program is 
     designated as a National Drug Control Program--
       (1) by the President; or
       (2) jointly by--
       (A) in the case of the National Intelligence Program, the 
     Director and the Director of National Intelligence; or
       (B) in the case of the Military Intelligence Program, the 
     Director, the Director of National Intelligence, and the 
     Secretary of Defense.
       (b) Classified Information.--Any contents of any report 
     required under this Act, or the amendments made by this Act, 
     that involve information properly classified under criteria 
     established by an Executive order shall be presented to 
     Congress separately from the rest of such report.
       (c) Use of Existing Resources.--To the extent practicable, 
     the Director and the head of each agency shall use existing 
     procedures and systems to carry out agency requirements under 
     this Act, and the amendments made by this Act.

     SEC. 6. GAO AUDIT AND REPORTS.

       Not later than three and six years after the date of the 
     enactment of this Act, the Comptroller General shall--
       (1) conduct an audit relating to the programs and 
     operations of--
       (A) the Office; and

[[Page H5321]]

       (B) certain programs within the Office, including--
       (i) the High Intensity Drug Trafficking Areas Program;
       (ii) the Drug-Free Communities Program; and
       (iii) the campaign under section 1009(d) of title 31, as 
     added by section 2(c); and
       (2) submit to the Director and the appropriate 
     congressional committees a report containing an evaluation of 
     and recommendations on the--
       (A) policies and activities of the programs and operations 
     subject to the audit;
       (B) economy, efficiency, and effectiveness in the 
     administration of the reviewed programs and operations; and
       (C) policy or management changes needed to prevent and 
     detect fraud and abuse in such programs and operations.

     SEC. 7. REPEALS.

       (a) Repeals to the Law.--The following provisions are 
     repealed:
       (1) The Office of National Drug Control Policy 
     Reauthorization Act of 1998 (Public Law 105-277; 21 U.S.C. 
     1701 et seq.).
       (2) Chapter 2 of the National Narcotics Leadership Act of 
     1988 (Public Law 100-690; 21 U.S.C. 1501 et seq.).
       (3) Section 203 of the Office of National Drug Control 
     Policy Reauthorization Act of 2006 (Public Law 109-469; 21 
     U.S.C. 1708a).
       (4) Section 1105 of the Office of National Drug Control 
     Policy Reauthorization Act of 2006 (Public Law 109-469; 21 
     U.S.C. 1701 note).
       (5) Section 1110 of Office of National Drug Control Policy 
     Reauthorization Act of 2006 (Public Law 109-469; 21 U.S.C. 
     1705 note).
       (6) Section 1110A of the Office of National Drug Control 
     Policy Reauthorization Act of 2006 (Public Law 109-469; 21 
     U.S.C. 1705 note).
       (7) Section 4 of Public Law 107-82 (21 U.S.C. 1521 note).
       (b) Effect on the Code.--The Law Revision Counsel shall 
     ensure that the website and any other publication issued 
     after the date of the enactment of this Act for the Office of 
     the Law Revision Counsel shows that the laws reflected in 
     subchapter II of chapter 20 and chapter 22 of nonpositive law 
     title 21 of the United States Code have been repealed.

     SEC. 8. DEFINITIONS.

       In this Act, the terms ``agency'', ``appropriate 
     congressional committees'', ``Director'', ``drug'', 
     ``emerging drug threat,'' ``illicit drug use'', ``illicit 
     drugs'', ``National Drug Control Program Agencies'', and 
     ``Office'' have the meaning given those terms in section 1001 
     of title 31, United States Code, as added by section 2(c).

  The SPEAKER pro tempore. Pursuant to the rule, the gentleman from 
Michigan (Mr. Mitchell) and the gentleman from Maryland (Mr. Cummings) 
each will control 20 minutes.
  The Chair recognizes the gentleman from Michigan.


                             general leave

  Mr. MITCHELL. Mr. Speaker, I ask unanimous consent that all Members 
may have 5 legislative days in which to revise and extend their remarks 
and include extraneous material on the bill under consideration.
  The SPEAKER pro tempore. Is there objection to the request of the 
gentleman from Michigan?
  There was no objection.
  Mr. MITCHELL. Mr. Speaker, I yield myself such time as I may consume.
  Mr. Speaker, I rise today in support of H.R. 5925, introduced by the 
gentleman from South Carolina, Chairman Gowdy.
  The Coordinated Response through Interagency Strategy and Information 
Sharing, or CRISIS, Act is a bill to reauthorize the Office of National 
Drug Control. This relatively small office plays an important role in 
coordinating the Nation's drug control efforts. The office has become 
increasingly important as we look to engage governmentwide initiatives 
to combat the opioid epidemic.
  Over the past 2 weeks, we have passed many good bills to help combat 
the opioid epidemic. Each will move us closer to ending the opioid 
crisis.
  This bill is a critical piece of the puzzle. It ensures Federal, 
State, and local governments work with each other and other 
nongovernmental entities to achieve the results we are seeking. 
Congress needs to provide the Office of National Drug Control the 
authorities it needs to lead the effort to combat the opioid crisis. 
The CRISIS Act does just that.
  The CRISIS Act updates and reaffirms the office's important role. 
That includes strengthening certain authorities to empower the office 
in the midst of this devastating epidemic.
  The opioid epidemic has impacted nearly every community across the 
Nation. One person dies about every 4 hours from an opioid overdose. 
One of the most important aspects of this bill is a comprehensive 
response plan. It is not enough to simply have a plan. We need action 
and follow-through to end the opioid crisis.
  The CRISIS Act requires measurable objectives so we know whether the 
programs we are funding are working.
  Accountability is at the heart of this bill. The CRISIS Act requires 
the Office of National Drug Control to develop a national strategy to 
be carried out by a wide array of agencies. It then requires the office 
to oversee and coordinate implementation of that strategy each year. It 
requires the office to measure whether the agencies are meeting the 
specific goals of that strategy.
  Our colleagues in the House and Senate are advancing a number of 
bills to address the opioid epidemic, and new initiatives are being 
announced daily. I offered an amendment in committee markup, with the 
support of Congressman Raskin, which brings in requirements from the 
CODE RED Act, sponsored by the gentleman from Pennsylvania (Mr. 
Rothfus).
  The CODE RED Act and the amendment require a coordinated tracking 
system of the Federal funding to be put toward drug control efforts 
throughout the country. This system includes a central repository of 
grants related to substance abuse treatment, prevention, and 
enforcement, and to identify those which are duplicative.
  The government needs to know exactly what it is spending, where it is 
going, and if it is working. This is not the time to invest in 
ineffective strategies. We need to identify resources that work and 
apply Federal resources accordingly.
  I would like to thank my fellow committee members for accepting the 
amendment, the gentleman from Maryland (Mr. Raskin) for offering it 
with me, and, of course, Mr. Rothfus for all the work he has done in 
finding an effective approach to tackle the opioid crisis.
  There are many bills and proposals that seek to end the opioid 
crisis, but it will only be possible with commitment to a coordinated 
strategy and a unified approach. This bill, through the reauthorization 
of the Office of National Drug Control, will provide the coordination, 
strategy, and unified approach we need.
  This is an important and timely bill. I urge my colleagues to support 
it, and I reserve the balance of my time.

         House of Representatives, Committee on Oversight and 
           Government Reform,
                                     Washington, DC, June 5, 2018.
     Hon. Edward Royce,
     Chairman, Committee on Foreign Affairs,
     House of Representatives, Washington, DC.
       Dear Mr. Chairman: On May 23, 2018, the Committee on 
     Oversight and Government Reform ordered reported H.R. 5925, 
     the ``Coordinated Response through Interagency Strategy and 
     Information Sharing Act,'' with an amendment, by voice vote. 
     The bill was referred primarily to the Committee on Oversight 
     and Government Reform, with additional referrals to the 
     Committees on Energy and Commerce, Foreign Affairs, the 
     Judiciary, Intelligence, and Appropriations.
       I ask you allow the Committee on Foreign Affairs to be 
     discharged from further consideration of the bill so it may 
     be scheduled for floor consideration by the Majority Leader. 
     This discharge in no way affects your jurisdiction over the 
     subject matter of the bill, and it will not serve as 
     precedent for future referrals. In addition, should a 
     conference on the bill be necessary, I would support your 
     request to have the Committee on Foreign Affairs represented 
     on the conference committee. Finally, I would be pleased to 
     include this letter and any response in the bill report filed 
     by the Committee on Oversight and Government Reform, as well 
     as in the Congressional Record during floor consideration, to 
     memorialize our understanding.
       Thank you for your consideration of my request.
           Sincerely,
     Trey Gowdy.
                                  ____

                                         House of Representatives,


                                 Committee on Foreign Affairs,

                                     Washington, DC, June 5, 2018.
     Hon. Trey Gowdy,
     Chairman, Committee on Oversight and Government Reform, 
         Washington, DC.
       Dear Chairman Gowdy: Thank you for consulting with the 
     Committee on Foreign Affairs on H.R. 5925, the Coordinated 
     Response through Interagency Strategy and Information Sharing 
     Act, and for accommodating appropriate edits in the amended 
     text of the bill.
       I agree that the Foreign Affairs Committee may be 
     discharged from further action on this bill, subject to the 
     understanding that this waiver does not in any way diminish 
     or alter the jurisdiction of the Foreign Affairs Committee, 
     or prejudice its jurisdictional prerogatives on this bill or 
     similar legislation in the future. The Committee also 
     reserves the right to seek an appropriate number of conferees 
     to any House-Senate conference involving this bill, and would 
     appreciate your support for any such request.

[[Page H5322]]

       I ask that you place our exchange of letters into the 
     Congressional Record during floor consideration of the bill. 
     I appreciate your cooperation, and look forward to continuing 
     to work with you as this measure moves through the 
     legislative process.
           Sincerely,
                                                  Edward R. Royce,
     Chairman.
                                  ____

         House of Representatives, Committee on Oversight and 
           Government Reform,
                                     Washington, DC, June 8, 2018.
     Hon. Devin Nunes,
     Chairman, Permanent Select Committee on Intelligence, House 
         of Representatives, Washington, DC.
       Dear Mr. Chairman: On May 23, 2018, the Committee on 
     Oversight and Government Reform ordered reported H.R. 5925, 
     the ``Coordinated Response through Interagency Strategy and 
     Information Sharing Act,'' with an amendment, by voice vote. 
     The bill was referred primarily to the Committee on Oversight 
     and Government Reform, with additional referrals to the 
     Committees on Energy and Commerce, Foreign Affairs, the 
     Judiciary, Intelligence, and Appropriations.
       I ask you allow the Permanent Select Committee on 
     Intelligence to be discharged from further consideration of 
     the bill so it may be scheduled for floor consideration by 
     the Majority Leader. This discharge in no way affects your 
     jurisdiction over the subject matter of the bill, and it will 
     not serve as precedent for future referrals. In addition, 
     should a conference on the bill be necessary, I would support 
     your request to have the Permanent Select Committee on 
     Intelligence represented on the conference committee. 
     Finally, I would be pleased to include this letter and any 
     response in the bill report filed by the Committee on 
     Oversight and Government Reform, as well as in the 
     Congressional Record during floor consideration, to 
     memorialize our understanding.
       Thank you for your consideration of my request.
           Sincerely,
     Trey Gowdy.
                                  ____

         House of Representatives, Permanent Select Committee on 
           Intelligence,
                                    Washington, DC, June 11, 2018.
     Hon. Trey Gowdy,
     Chairman, Committee on Government and Oversight Reform, House 
         of Representatives, Washington, DC.
       Dear Mr. Chairman: On May 23, 2018, H.R. 5925, the 
     ``Coordinate Response through Interagency Strategy and 
     Information Sharing Act'' was additionally referred to the 
     Permanent Select Committee on Intelligence.
       In order to expedite the House's consideration of the 
     measure, and in response to your letter dated June 8, 2018, 
     the Permanent Select Committee on Intelligence will forgo 
     consideration of the measure. This courtesy is conditioned on 
     our mutual understanding and agreement that it will in no way 
     diminish or alter the jurisdiction of the Permanent Select 
     Committee on Intelligence with respect to any future 
     jurisdictional claim over the subject matter contained in the 
     resolution or any similar measure. I appreciate your support 
     to the appointment of Members from the Permanent Select 
     Committee on Intelligence to any House-Senate conference on 
     this legislation.
       I would appreciate you including our exchange of letters in 
     the Congressional Record during floor consideration of H.R. 
     5925. Thank you for the cooperative spirit in which you have 
     worked regarding this and other matters between our 
     respective committees.
           Sincerely,
                                                      Devin Nunes,
     Chairman.
                                  ____

         House of Representatives, Committee on Oversight and 
           Government Reform,
                                    Washington, DC, June 18, 2018.
     Hon. Rodney Frelinghuysen,
     Chairman, Committee on Appropriations,
     House of Representatives, Washington, DC.
       Dear Mr. Chairman: On May 23, 2018, the Committee on 
     Oversight and Government Reform ordered reported H.R. 5925, 
     the Coordinated Response through Interagency Strategy and 
     Information Sharing Act, with an amendment, by voice vote. 
     The bill was referred primarily to the Committee on Oversight 
     and Government Reform, with additional referrals to the 
     Committees on Energy and Commerce, Foreign Affairs, the 
     Judiciary, Intelligence, and Appropriations.
       I ask you allow the Committee on Appropriations to be 
     discharged from further consideration of the bill so it may 
     be scheduled for floor consideration by the Majority Leader. 
     This discharge in no way affects your jurisdiction over the 
     subject matter of the bill, and it will not serve as 
     precedent for future referrals. In addition, should a 
     conference on the bill be necessary, I would support your 
     request to have the Committee on Appropriations represented 
     on the conference committee. Finally, I would be pleased to 
     include this letter and any response in the bill report filed 
     by the Committee on Oversight and Government Reform, as well 
     as in the Congressional Record during floor consideration, to 
     memorialize our understanding.
       Thank you for your consideration of my request.
           Sincerely,
     Trey Gowdy.
                                  ____

                                         House of Representatives,


                                  Committee on Appropriations,

                                    Washington, DC, June 19, 2018.
     Hon. Trey Gowdy,
     Chairman, Committee on Oversight and Government Reform, House 
         of Representatives, Washington, DC.
       Dear Mr. Chairman: Thank you for your letter regarding H.R. 
     5925, the Coordinated Response through Interagency Strategy 
     and Information Sharing Act. As you know, certain provisions 
     of the bill fall within the jurisdiction of Committee on 
     Appropriations.
       So that H.R. 5925 may proceed expeditiously to the House 
     Floor, I agree to discharging the Committee on Appropriations 
     from further consideration thereof, subject to the 
     understanding that forgoing formal consideration of the bill 
     will not prejudice the Committee on Appropriations with 
     respect to any future jurisdictional claim. The Committee on 
     Appropriations also reserves the right to seek an appropriate 
     number of conferees to any House-Senate conference on this or 
     related legislation.
       I request you include our exchange of letters in the bill 
     report filed by your Committee, as well as in the 
     Congressional Record during consideration of the bill on the 
     floor.
           Sincerely,
     Rodney P. Frelinghuysen.
                                  ____

         House of Representatives, Committee on Oversight and 
           Government Reform,
                                    Washington, DC, June 19, 2018.
     Hon. Bob Goodlatte,
     Chairman, Committee on the Judiciary,
     House of Representatives, Washington, DC.
       Dear Mr. Chairman: On May 23, 2018, the Committee on 
     Oversight and Government Reform ordered reported H.R. 5925, 
     the Coordinated Response through Interagency Strategy and 
     Information Sharing Act, with an amendment, by voice vote. 
     The bill was referred primarily to the Committee on Oversight 
     and Government Reform, with additional referrals to the 
     Committees on Energy and Commerce, Foreign Affairs, the 
     Judiciary, Intelligence, and Appropriations.
       I ask you allow the Committee on the Judiciary to be 
     discharged from further consideration of the bill so it may 
     be scheduled for floor consideration by the Majority Leader. 
     This discharge in no way affects your jurisdiction over the 
     subject matter of the bill, and it will not serve as 
     precedent for future referrals. In addition, should a 
     conference on the bill be necessary, I would support your 
     request to have the Committee on the Judiciary represented on 
     the conference committee. Finally, I would be pleased to 
     include this letter and any response in the bill report filed 
     by the Committee on Oversight and Government Reform, as well 
     as in the Congressional Record during floor consideration, to 
     memorialize our understanding.
       Thank you for your consideration of my request.
           Sincerely,
     Trey Gowdy.
                                  ____

         House of Representatives, Committee on Oversight and 
           Government Reform,
                                    Washington, DC, June 19, 2018.
     Hon. Greg Walden,
     Chairman, Committee on Energy and Commerce,
     House of Representatives, Washington, DC.
       Dear Mr. Chairman: On May 23, 2018, the Committee on 
     Oversight and Government Reform ordered reported H.R. 5925, 
     the Coordinated Response through Interagency Strategy and 
     Information Sharing Act, with an amendment, by voice vote. 
     The bill was referred primarily to the Committee on Oversight 
     and Government Reform, with additional referrals to the 
     Committees on Energy and Commerce, Foreign Affairs, the 
     Judiciary, Intelligence, and Appropriations.
       I ask you allow the Committee on Energy and Commerce to be 
     discharged from further consideration of the bill so it may 
     be scheduled for floor consideration by the Majority Leader. 
     This discharge in no way affects your jurisdiction over the 
     subject matter of the bill, and it will not serve as 
     precedent for future referrals. In addition, should a 
     conference on the bill be necessary, I would support your 
     request to have the Committee on Energy and Commerce 
     represented on the conference committee. Finally, I would be 
     pleased to include this letter and any response in the bill 
     report filed by the Committee on Oversight and Government 
     Reform, as well as in the Congressional Record during floor 
     consideration, to memorialize our understanding.
       Thank you for your consideration of my request.
           Sincerely,
                                                       Trey Gowdy.

  Mr. CUMMINGS. Mr. Speaker, I yield myself such time as I may consume.
  Mr. Speaker, I want to thank Chairman Gowdy for his leadership and 
for working together to craft this legislation. I thank Chairman 
Meadows and Ranking Member Connolly for helping us reach the 
compromises that made this legislation possible.
  In 1988, Mr. Speaker, Congress created the Office of National Drug 
Control Policy. This is the office that should be coordinating our 
Nation's drug control efforts and leading our response to the drug 
crisis, which is now,

[[Page H5323]]

by the way, killing 175 people per day. Let me repeat that: killing 175 
people per day.
  However, ONDCP is failing, just when we need it the most. In fact, an 
article published this week described the office this way: ``empty 
desks, squabbles, inexperienced staff.''
  The failure is glaring. For example, the office is required to 
produce a national drug control strategy by February 1 of each year. 
Two February 1sts have now come and two have gone since President Trump 
took office, but the Trump administration still has not come up with a 
solution to this most glaring and painful problem. This is simply 
unacceptable.
  Life expectancy in this Nation is falling because we are failing to 
respond appropriately to this drug crisis. We urgently need to 
revitalize and strengthen ONDCP.
  H.R. 5925, the CRISIS Act, would make changes we need and would 
improve our drug control efforts if it is fully funded and 
implemented--fully funded and implemented.

                              {time}  1215

  It would expand the office's authority to direct resources where they 
are most needed. It would strengthen data collection and analysis to 
help us develop the real-time monitoring we need to understand the 
rapidly changing dimensions of the opioid crisis.
  The bill incorporates several proposals I have offered to give ONDCP 
new authorities to coordinate critical aspects of our response to the 
crisis.
  I have often said that we must go about the business of being 
effective and efficient in what we do. These are examples of things 
that will make ONDCP more effective and efficient in addressing this 
problem.
  For example, for the first time ever, it would create a treatment 
coordinator within the office responsible for coordinating efforts to 
expand the availability and quality of evidence-based treatment.
  It would also require the office to develop and promulgate model 
standards for treatment facilities. Right now, too many so-called 
treatment facilities are taking advantage of desperate families, 
charging them outlandish prices, bilking insurance companies, but 
failing to help those in need. As a matter of fact, many people are 
going into these places seeking to get treatment and come out worse off 
because they are not being properly treated.
  Remember what I said: We want to be effective and efficient in what 
we do, and we want to make sure that taxpayers' dollars are spent 
appropriately.
  I believe that if H.R. 5925 is enacted and fully implemented, it will 
improve our drug control efforts, and, for that reason, I am supporting 
the measure.
  However, I want to be real clear about something. Even if this bill 
is enacted and fully implemented, the drug crisis we are facing will 
likely get worse. That is because this bill does not provide the 
resources we need to treat millions of Americans who have the disease 
of addiction. According to the President's own commission on opioids, 
only 10 percent of individuals who need treatment for substance abuse 
disorders are getting it.
  No one believes that we can fight cancer, or heart disease, or 
Alzheimer's if we don't treat people who have these diseases. The same 
is true here.
  Imagine someone going into a doctor's office and the doctor says: 
Well, you are the 10th person, and you are lucky to get treatment. But 
the other nine who came before you won't get any treatment.
  We will not stand for that. If we don't treat people who are 
addicted, we will not solve the drug crisis.
  We may pass this bill today, celebrate the passage, and say we did a 
great job. We may work with the Senate to send it to the President. The 
President might even sign it. But then, next year's overdose fatality 
numbers will come out. They will show that deaths are continuing to 
rise. They will show emergency room visits increasing again. They will 
show the economic effects of a crisis that is already costing us $500 
billion a year continuing to grow.
  It doesn't have to be this way. No, it doesn't have to be this way. 
We don't have to just nibble at the edges or rearrange the deck chairs 
on the Titanic.
  I have introduced legislation called the CARE Act with Senator 
Elizabeth Warren, modeled directly on the highly successful Ryan White 
Act, which Congress passed with bipartisan support in 1990 to address 
the AIDS crisis.
  The CARE Act would provide $10 billion a year in stable, predictable 
Federal funding to States, counties, and other frontline responders. 
The CARE Act would provide funds for research to train health 
professionals to diagnose and treat addiction. It would also provide 
half a billion dollars per year to purchase the lifesaving drug 
naloxone at discounted prices and distribute it to first responders, 
public health agencies, and the public.
  I offered the CARE Act as an amendment to this measure considered 
this week. My amendment was paid for by rolling back just a portion of 
the tax cuts given by the Republican-controlled Congress to the 
Nation's largest corporations, including the drug companies who have 
used their tax breaks to buy back billions of dollars' worth of stock 
rather than lower drug prices. By the way, there is something wrong 
with that picture.
  But the Republican leadership did not make my amendment in order. The 
House never considered it.
  I support H.R. 5925 and our critical efforts to ensure that we have 
an office that will effectively and efficiently coordinate our drug 
control efforts. However, what our Nation truly needs is for us to show 
the political courage to choose to save the lives of our fellow 
Americans by adequately funding treatment.
  Mr. Speaker, I reserve the balance of my time.
  Mr. MITCHELL. Mr. Speaker, I yield myself such time as I may consume.
  Mr. Speaker, I appreciate the support of my colleague for this 
bipartisan effort to address the opioid crisis in this country. I also 
appreciate his emphasis on effectively and efficiently addressing that 
crisis.
  I will note that in the last appropriation cycle, we increased 
funding for opioid treatment by almost $4 billion in this year alone. 
There is much work to be done; it is a crisis; and we will work 
together to address that crisis.
  Mr. Speaker, I yield 5 minutes to the gentleman from North Carolina 
(Mr. Meadows), the cosponsor of the bill.
  Mr. MEADOWS. Mr. Speaker, I thank the gentleman for his leadership on 
this particular initiative in managing this bill.
  Mr. Speaker, I rise in support of H.R. 5925, the CRISIS Act, a bill I 
cosponsored with Chairman Gowdy; my good friend, the ranking member, 
Mr. Cummings; as well as the ranking member of the Government 
Operations Subcommittee and good friend, Mr. Connolly.
  I want to begin by thanking my colleagues for coming together on this 
bipartisan bill. H.R. 5925 reauthorizes the Office of National Drug 
Control Policy and gives the office greater responsibility by enhancing 
the office's authority to coordinate and oversee the national 
drug control program at the national, State, and local levels.

  It provides communities with a process for sharing information and 
best practices, and implements recommendations from the President's 
opioid commission.
  It requires an opioid response plan to coordinate with the private 
sector the implementation of the commission's recommendations and to 
facilitate the development of treatment and abuse-deterrent products.
  Finally, this bill designates the United States Postal Service as a 
national drug control program agency and requires the office to 
coordinate actions to reduce the flow of illicit drugs entering the 
country through the mail.
  The ongoing opioid epidemic has taken countless lives, touching 
literally every community in the country. The national response to this 
epidemic involves Federal, State, and local governments. It involves 
the treatment community, the medical community, the law enforcement 
community, and places of worship.
  As we mobilize a national response, we must ensure that every effort 
to combat this epidemic works and works well. We have all heard too 
many tragic, life-changing, and, far too often, life-ending stories of 
opioid addiction.
  There is no easy way to end this epidemic. By establishing an 
effective national response to this epidemic, this bill will support 
the people and the communities struggling with this addiction.

[[Page H5324]]

  Mr. Speaker, it is the very lives of our friends, our neighbors, and 
our family members that depend on us.
  Mr. Speaker, I urge my colleagues to support this bill.
  I would also like to go a little bit further, though, because so many 
times, when we come together in a bipartisan way, it is Members of 
Congress who are up here taking the credit for the hard work of a group 
that actually, behind the scenes, are doing the work. I thank all of 
the majority staff--Katy Rother, Richard Burkard, Betsy Ferguson, and 
Sarah Vance; and to Ranking Member Cummings' staff, for all of their 
work and dedication as well. And I also thank Sally Walker from the 
Office of Legislative Counsel. Many times, they do the work on the 
bills behind the scene and nobody ever sees them or thanks them. So, on 
this day, I want to make sure that we acknowledge their effort, that it 
doesn't go unnoticed.
  Mr. CUMMINGS. Mr. Speaker, I yield myself such time as I may consume.
  Mr. Speaker, I want to take a moment, before I yield to my 
distinguished colleague, Mr. Connolly, to echo what my good friend just 
said about our staffs.
  I, too, thank our staffs for all that they have done. So often they 
are unseen, unnoticed, and feel, I am sure, unappreciated and 
unapplauded. But our staffs worked very, very hard on this, and I, too, 
give the ultimate applause to them. I want to thank you for recognizing 
them.
  Mr. Speaker, I also thank Mr. Meadows for working so hard to bring 
all this together.
  Mr. Speaker, I yield 6 minutes to the gentleman from Virginia (Mr. 
Connolly), the ranking member of the Oversight and Government Reform 
Committee, a man who has just been tireless on this issue and so many 
others, but who has done such a phenomenal job.
  Mr. CONNOLLY. Mr. Speaker, I thank my friend from Michigan (Mr. 
Mitchell) and my good friend from North Carolina (Mr. Meadows) for 
their leadership. But I particularly want to thank my good friend from 
Maryland (Mr. Cummings).
  Mr. Cummings is not only a legislative expert, but he is also a moral 
voice. He speaks with clarity and eloquence, as he did yesterday, about 
innocent children being detained at the southern border as an un-
American activity, something that does not reflect our values. And 
today, he is lending that same moral voice to the crisis that afflicts 
so many communities in America: the opioid addiction crisis.
  Mr. Speaker, I rise today in support of the Coordinated Response 
through Interagency Strategy and Information Sharing Act, or the CRISIS 
Act, to reauthorize and revamp the Office of National Drug Control 
Policy.
  The chairman and ranking member of our full committee worked closely 
together and with committee members to produce a bipartisan bill that 
was reported out of the committee unanimously.
  I am proud to be an original cosponsor of the CRISIS Act, which not 
only reauthorizes ONDCP, but also strengthens that office so that it 
has the resources it needs to coordinate an effective response to the 
opioid crisis. And that is something Mr. Cummings stressed. It is not 
good enough to do something symbolic. We have to ensure it is 
effective. ONDCP's responsibilities are to produce a national drug 
control strategy.

                              {time}  1230

  Congress created it in 1988 at the height of the crack cocaine 
epidemic to oversee Federal drug control efforts and to advise the 
President and the administration on drug control policies and 
strategies.
  It was designed to oversee the National Drug Control Budget to carry 
out the goals and policies of that strategy, and to evaluate the 
effectiveness of programs across the Federal Government in implementing 
the strategy, and to oversee the High Intensity Drug Trafficking Areas 
and Drug Free Communities initiatives.
  Congress last authorized the ONDCP in 2006. The authorization expired 
in 2010. That is 8 years ago. Since then, we have developed an opioid 
crisis the magnitude of which we have never seen in America.
  While ONDCP has continued to receive annual appropriations, it is 
important that Congress reauthorize this program and reflect the crisis 
we are in.
  The opioid epidemic that is currently ravaging communities has taken 
hundreds of thousands of lives and shows no signs of abating. Every 
day, 115 Americans die from an opioid overdose.
  The epidemic is destroying families, overwhelming first responders, 
straining public health, criminal justice, and child welfare resources.
  This epidemic doesn't care where you live or what political party you 
belong to. The crisis has touched every community and every corner of 
our country.
  In my State, the Commonwealth of Virginia, opioid overdose deaths 
spiked by 40 percent to 1,133 from 2015 to 2016, and deaths from 
synthetic opioids rose from 263 to 692 during that time period.
  Northern Virginia, where I represent the good people of Fairfax and 
Prince William Counties, Fairfax County, for example, reported an 
increase from 67 to 97 opioid-related deaths from 2015 to 2016. And 
Prince William County, the other county I represent, increased from 26 
to 59 deaths in this time period.
  Last month, Dr. Rahul Gupta, Commissioner of the West Virginia Bureau 
of Public Health, testified before our committee, and he said that the 
crisis will get worse before it gets better. That was not welcome news.
  Yet despite the President's pledges and his own Commission on 
Combating Drug Addiction and the Opioid Crisis recommendation that he 
declare an opioid crisis national emergency, the President, President 
Trump, took the lesser step of declaring a public health emergency last 
October.
  Seventeen months into this administration, ONDCP is still without a 
confirmed director and the administration has failed to produce a 
National Drug Control Strategy.
  Instead, the President, President Trump, proposed cutting ONDCP's 
budget by more than 90 percent. Thank goodness Congress, on a 
bipartisan basis, did not heed that recommendation.
  Just earlier this week, the acting head of the Drug Enforcement 
Agency announced he is going to be retiring at the end of the month, 
stating that running that agency in an acting capacity for so long had 
become increasingly challenging.
  As this administration continues to fail to address the opioid 
epidemic, it is imperative that we take immediate and decisive action 
on a bipartisan basis.
  Reauthorizing the Office of National Drug Control Policy with 
enhanced authorities will improve the coordination and effectiveness of 
Federal Government drug control efforts. It is one of the many steps we 
can take to address the opioid epidemic. It won't solve everything, but 
it is a very important first step.
  I hope the administration will join us in fighting this crisis with 
real solutions and not empty rhetoric.
  Mr. Speaker, I hope my colleagues will join us in supporting this 
important bill.
  Mr. MITCHELL. Mr. Speaker, I yield myself such time as I may consume.
  Mr. Speaker, I appreciate the support of my colleague from Virginia 
(Mr. Connolly) for this bipartisan effort. I certainly hope the 
American people have the opportunity to see this effort as we address 
this crisis on a bipartisan basis. Far too frequently, they see 
conflict and disagreement put forth by media and other sources, but 
there is a great deal we work together on, and I think we need to 
stress that as we talk to people about this crisis.
  Mr. Speaker, in a moment, I will yield to the gentleman from 
Pennsylvania (Mr. Rothfus), but first let me give him credit, because 
he is the sponsor of legislation on which my amendment was based, H.R. 
5980, the CODE RED Act.
  The CODE RED Act, like the amendment I offered with Mr. Raskin in 
committee, requires a coordinated tracking system of Federal funding 
put towards drug control efforts throughout our country. It is a smart 
idea, especially given the opioid epidemic in our Nation and the costs 
of it, and I strongly supported it.
  Mr. Speaker, I yield 5 minutes to the gentleman from Pennsylvania 
(Mr. Rothfus).
  Mr. ROTHFUS. Mr. Speaker, I thank Mr. Mitchell for yielding.

[[Page H5325]]

  Mr. Speaker, I rise in support of H.R. 5925, the Coordinated Response 
through Interagency Strategy and Information Sharing Act, or the CRISIS 
Act.
  This bill reauthorizes the Office of National Drug Control Policy, 
which has not been reauthorized in a very long time. It makes needed 
overhauls and updates to the office and even streamlines the name of 
the office to the Office of National Drug Control, or ONDC.
  Mr. Speaker, I commend Chairman Gowdy and Ranking Member Cummings for 
working in a bipartisan manner. I also thank Representative Mitchell 
and Representative Raskin for working with me to incorporate the first 
two recommendations of the President's opioid commission into the 
CRISIS Act.
  I introduced a separate bill, the Coordinated Overdose and Drug 
Epidemic Response to the Emergency Declaration Act, or CODE RED Act, 
that authorizes ONDC to address those commission recommendations.
  ONDC will now be authorized to implement a coordinated tracking 
system of all federally-funded initiatives and grants. This will help 
identify barriers and gaps in Federal efforts responding to the opioid 
crisis and it identifies places where efforts are being duplicated and 
potentially wasted. This legislation improves the grant application 
process by standardizing and streamlining it.

  The mission here is to deploy Federal resources to localities that 
need them quickly and efficiently instead of localities wasting 
valuable time and resources filling out various agency applications.
  More broadly, the CRISIS Act will foster better government 
coordination and strategic planning. ONDC has cross-agency jurisdiction 
to coordinate the efforts among different agencies, like HHS and DOJ. 
When agencies work together, the force-multiplying effect can make a 
huge difference.
  We are making progress on the opioid crisis. Bipartisan bills like 
the CRISIS Act will help win this fight and help the people engage in 
the fight, like the North Hills of Pittsburgh's Tracy Lawless.
  Tracy participated in the President's Commission on Combating Drug 
Addiction and continues to help find solutions back in Pennsylvania.
  Mr. Speaker, I thank her and everyone else who is making a 
difference.
  Mr. MITCHELL. Mr. Speaker, I want to make the gentleman from Maryland 
aware that I have no further speakers and I am prepared to close.
  Mr. Speaker, I reserve the balance of my time.
  Mr. CUMMINGS. Mr. Speaker, I yield myself such time as I may consume.
  Mr. Speaker, in closing, I must point out that my Republican 
colleagues say they want to address the opioid crisis, yet they are 
standing silent as the Trump administration actively tries to destroy 
the Affordable Care Act protections for people with pre-existing 
conditions, which, by the way, includes substance use disorders.
  If we aren't going to take available steps to expand access to 
addiction treatment, at least we should all agree that we shouldn't 
roll back protections that prevent insurance companies from 
discriminating against people with substance use disorders. Therefore, 
we should all be working to protect the Affordable Care Act from the 
Trump administration's effort to destroy the essential protections it 
provides.
  Again, I remind all of us that ONDCP is a very important entity and 
it has a job to do, and it must be properly funded.
  A lot of people, when they give statistics about opioids and drugs, 
Mr. Speaker, they find themselves speaking about the dead. Well, I am 
here to tell you that there are pipelines to death, and those are the 
people who are addicted now. Those are the ones who are thinking about 
it, about to start using those drugs. So we must address not only the 
deaths and the statistics, but we must address treatment that is 
effective and efficient.
  Mr. Speaker, again, I am urging my colleagues to vote for this bill, 
but I want it to be clear that we should not dust our hands off and say 
it is done.
  It is not done. There is so much more to do.
  Mr. Speaker, I urge all Members to vote for this legislation, and I 
yield back the balance of my time.
  Mr. MITCHELL. Mr. Speaker, I yield myself the balance of my time.
  Mr. Speaker, I appreciate my colleague's support of the bill. In my 
brief time here, a year and a half, it has become abundantly clear to 
me that rarely do we get to dust off our hands and say we are done 
around here.
  It has also become clear to me that the debate of the bill rarely 
stays on the topic of the bill or solely on the topic of the bill. You 
see, the ACA, the Affordable Care Act, is not the sole approach to 
addressing healthcare issues in this country, preexisting conditions, 
or the preexisting conditions that are affected by drug abuse.
  I believe when we passed the American Health Care Act in this House, 
that that addressed preexisting conditions, treatment for substance 
abuse, and, using the words of my colleague, did so more effectively 
and efficiently than the Affordable Care Act does now.
  We clearly disagree on that. I respect that, and will continue to 
work on it.
  Today, we are dealing with this bill.
  Mr. Speaker, I urge my colleagues to support passage of this bill, 
because I believe that H.R. 5925 is an important step not only in 
reauthorizing the Office of National Drug Control, but also in 
providing additional resources to do so.
  Mr. Speaker, I urge adoption the bill, and I yield back the balance 
of my time.
  The SPEAKER pro tempore (Mr. Meadows). The question is on the motion 
offered by the gentleman from Michigan (Mr. Mitchell) that the House 
suspend the rules and pass the bill, H.R. 5925, as amended.
  The question was taken; and (two-thirds being in the affirmative) the 
rules were suspended and the bill, as amended, was passed.
  A motion to reconsider was laid on the table.

                          ____________________